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Foreword
The enlargement of the European Union next year means
that this is the last time that the EMCDDA will produce an
annual report exclusively devoted to the drugs phenomenon
in the acceding and candidate countries. It is appropriate,
therefore, to take this opportunity to reflect on the historical
evolution of the drug phenomenon in these countries and,
at the same time, focus in detail on some of the key issues
facing the region.
In terms of an effective response to the drugs problem, the
enlargement of the European Union presents us with both
challenges and opportunities. So far we have heard more
about the potential problems that we may face rather than
the benefits that can accrue from closer collaboration. In
this report we seek to redress this imbalance. We cannot
ignore the concerns of those who fear that an increase in
drug trafficking from and through the central and east
European countries will result from relaxation of border
restrictions and greater free movement of goods and
individuals. Nor can we ignore the concerns expressed by
some new Member States that greater integration will result
in escalating drug use among young people in communities
in which drug problems were previously rare. We
recognise, however, that both drug trafficking and the
diffusion of drug use are independent of enlargement.
Increasingly, drug problems have shown the ability to
transcend national borders and, accordingly, the issue has
become a global one to which no country is immune. EU
enlargement provides us with the opportunity to work more
closely together to understand and respond to this shared
problem, based on a sound analysis of its nature and a
developing understanding of what is likely to constitute
effective action. This is the positive message that emerges
from this report and is also reflected in the accompanying
annual report on the drugs situation in the EU and Norway.
This review of key aspects of the drug situation leads us to
a number of important conclusions. Central to these is that
reliable and relevant information is essential for
underpinning the new drug strategies and policies that are
under development in all acceding and candidate countries.
This need is not currently reflected in capacity, and all
countries covered by this report need to invest in
developing the surveillance and reporting systems
necessary for a sound understanding of the phenomenon
and for tracking its evolution over time. In a region
undergoing such rapid change, the early detection of new
trends and emerging problems is likely to be of particular
importance, as is reacting quickly when new problems are
identified. The importance of this message is made clear
from a reading of the sections of this document that address
the potential for future HIV epidemics in many of the
countries under review.
Monitoring is important as it allows us to target our actions
and evaluate their impact. However, it is of little value if it
does not result in effective programmes and well-developed
interventions. It is therefore critically important that as
responses are developed they benefit from the work already
done in identifying what constitutes best practice. At
European level, this is part of the rationale for the existence
of the EMCDDA and the Reitox network. The national focal
points, together with other centres at regional and local
level, play a key role in this process by collecting and
synthesising the information needed for sound policy
development. This reminds us again that adequate and
sustained investment in the human infrastructure is
necessary for generating and disseminating information.
In reading this report, you may be struck by the thought
that in many areas the potential for the future development
of serious and destructive drug problems is acute. Drug
problems complicate and thrive on other social ills, and
communities undergoing social change may be particularly
vulnerable. This document illuminates these issues, and the
charting of the evolution of the drug phenomenon in the
region is perhaps one of the strongest aspects of this report.
However, we also hope that the reader reaches a positive
conclusion regarding the potential for the acceding and
candidate countries to play a full part in a concerted and
coordinated response to the European drugs problem. 
Marcel Reimen
Chairman, EMCDDA Management Board
Georges Estievenart
Executive Director, EMCDDA
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Note
The 10 countries acceding to the EU in 2004 are the Czech Republic, Cyprus, Estonia, Hungary, Latvia, Lithuania,
Malta, Poland, Slovakia and Slovenia. They are sometimes also referred to as the new Member States.
The three candidate countries aiming to join the EU are Bulgaria, Romania and Turkey (the first two are working
towards the objective of joining in 2007).
For the purpose of this report, the central and east European countries (CEECs) are Bulgaria, the Czech Republic,
Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia and Slovenia.
An online version of this report is available (http://candidates.emcdda.eu.int) which provides links to data sources,
national reports and background documents.
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(1) The 10 countries acceding to the EU in 2004 are the Czech Republic, Cyprus, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Slovakia and Slovenia.
They are sometimes also referred to as the new Member States.
(2) The three candidate countries aiming to join the EU are Bulgaria, Romania and Turkey (the first two are working towards the objective of joining in 2007).
(3) For the purpose of this report the CEECs are Bulgaria, the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia and Slovenia.
In 2004, the European Union will enlarge to 25 Member
States (1) with a prospect of a further expansion to
28 members in 2007 (2). The EMCDDA, with the support of
the Phare programme of the European Commission, has
been working with the acceding and candidate central and
east European countries (CEECs) (3) to build up a more
comprehensive picture of the drug phenomenon in the
region and also to prepare the CEECs for integration into
the EMCDDA European reporting structures. This report
marks the end of this preparatory phase of work and, in
the future, data from these countries will form part of the
overall picture of drug use in the European Union. It is
therefore appropriate to take this opportunity to reflect on
what has been learnt about the drug problem in the new
Member States, to look in detail at some of the key issues,
and to consider some of the likely challenges that will face
us in the future, in terms of both developing information
systems and responding to drug problems. To this end, this
report from the EMCDDA is structured around four specially
commissioned reviews prepared by experts with detailed
knowledge of the field and supported by information
collected as part of the technical cooperation between the
Centre and the acceding countries. The report also makes
use of the information available to the EMCDDA through
the 2002 national reports on the drug situation produced
by national drug information focal points (NFPs). Where
possible, data from Cyprus, Malta and Turkey are also
provided. 
Chapter 1 provides a historical and global overview of how
the drug situation and responses to drug problems
developed in the 1990s and early 2000s. This analysis is
placed in the broader contextual framework of the political,
economic and social changes that were occurring during
this period in central and eastern Europe. The emphasis is
on drug demand and its reduction and the implications for
the wider public health and social policy framework. The
chapter concludes by identifying some of the key challenges
that are likely to face candidate and acceding countries in
the region as they respond to more developed and
entrenched drug problems.
Drug use in central and eastern Europe is very much a
phenomenon of the young, and in public health terms has
to be seen also in the context of changing patterns of
alcohol consumption, a drug that has always had a
significant health impact in many countries in the region.
Patterns of drug use have to some extent been adopted by
young people as part of a broader development of youth
culture, music and fashion. These issues are explored in
Chapter 2, which looks in detail at what is known about the
changing picture of drug and alcohol use among the young
and also mirrors a similar focus piece in the accompanying
EMCDDA annual report on the state of the drugs problem
in the European Union and Norway. 
Although the prevalence of human immunodeficiency virus
(HIV) infection is low in most of the acceding and candidate
countries, a number of factors suggest that the potential for
serious future problems remains considerable. This
conclusion is reinforced by the recent and sudden increases
in HIV infection in the Baltic States and their neighbouring
countries to the east. Hepatitis C infection among drug
users is also likely to result in considerable long-term public
health costs. The increasing numbers of drug injectors in the
region, together with continuing high-risk behaviours,
suggests that strengthening public health measures to
prevent the spread of HIV and HCV among this group is a
critically important area for public health policy. For this
reason the issue of drug-related infectious diseases is the
subject of Chapter 3 of this report. 
Chapter 4 provides a descriptive review of the main
‘instruments’ of drug policy in the region, namely laws,
strategies and coordination arrangements in the field of
drugs. The chapter concludes that the new drug strategies
in the candidate countries are comprehensive and oriented
towards a global long-term approach; some are also
structured to monitor performance.
Introduction
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Historical overview
In this section, the evolution of the drugs situation during
the 1990s, in the historical context of political, economic
and social changes in central and eastern Europe,
is described.
Political, economic and social context
Since the break-up of the Soviet Union in 1989, the CEECs
have experienced rapid political, economic and social
changes. Despite important differences between the
countries in the manner, degree and rate of these changes,
there are common elements. Centralised, one-party systems
have generally been replaced by more decentralised,
multiparty structures, often accompanied by devolution
of powers to regional and local authorities. In addition,
economies have moved towards less regulated market
systems, social protection measures have been reduced and
many State monopolies have been broken up and
privatised. Open borders and convertible currencies have
stimulated increased mobility of goods, money and people
for both legal and illegal purposes.
These political and economic changes have had important
social impacts. Often, unemployment, previously almost
unknown in many CEECs, increased suddenly, and living
standards for many declined sharply. Although broad
economic indicators subsequently improved again, at least
in some countries, recovery has been uneven, and long-
term social dislocation still poses serious problems in some
communities, especially in areas of industrial or agricultural
decline. Increases in delinquency, prostitution, organised
crime and trafficking in drugs or persons are further
indicators of some of the negative consequences of political
and economic liberalisation. The changes have also had an
important impact upon the perceptions and expectations of
young people. Some commentators have referred to a crisis
of values and lack of social consensus that was reinforced
by mistrust of official structures and institutions and
reflected in intergenerational tensions. Although economic
changes may have brought many benefits, and while
political independence may have instilled a sense of identity
and pride, the strains induced by rapid social changes also
engendered uncertainty and a sense of vulnerability among
some sections of the community who felt that they were yet
to see the benefits of change.
Although the focus here is on the CEECs, their geopolitical
position means that any analysis of the situation in these
10 countries must be set in a wider regional context, in
particular taking account of developments following the
break-up of the former Soviet Union and the consequences
of the war in Yugoslavia. These have had, and continue to
have, major implications for the CEECs, for example in
terms of drug trafficking, organised crime, the position of
Russian minorities in some countries and the risks arising
from the HIV/AIDS epidemic in Russia and the Ukraine.
Historical evolution of the drug phenomenon
In all CEECs, the most widely used and the most
problematic psychoactive substance has been, and
continues to be, alcohol. Long-term trends over the past
four decades show large increases in consumption,
especially of spirits. More recent trends vary, with alcohol
use tending to stabilise in some, but increasing in most,
countries, particularly among young people, and especially
among young women. In addition to the influence of
domestic social and economic factors on alcohol use, since
1989 marketing has played an increasingly important role
in shaping patterns of both alcohol and tobacco
consumption. At the same time, the importance attached to
alcohol problems in both the public and political discourse
that was apparent in the years prior to 1989 has
diminished, despite increased consumption and the serious
individual and social costs of alcoholism.
Reliable data on the historical development of drug use are
scarce, as in the past official attitudes often reflected a
reluctance to acknowledge the existence of drug use, with
the result that little social research took place (although
there was some medico-biological research and official
registers of known users were maintained). Despite this,
it is possible to describe the general historical evolution
of the drug phenomenon.
In most of the CEECs, this evolution began before the
dramatic political landmark of 1989. For example, drug
Chapter 1
Overview of the drugs situation in the CEECs — situation and responses
This chapter provides a global overview of the drug situation in the acceding and candidate
central and east European countries (CEECs) and their responses over the past 10 to 15 years.
The emphasis is on drug demand and its reduction and the implications for the wider public
health and social policy framework.
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eneration. There was a time-lag before patterns of drug use
reflected this shift, partly because it takes time for new
ideas to diffuse and become established and manifest in
visible changes, especially when the cultural gap
perpetuated through ‘cold war’ rhetoric appeared so wide,
and partly because authoritarian structures and strict
border controls slowed both the expression of those ideas
and the development of new markets. Thus, there was a
disjunction between the official, mainstream discourse
and the largely hidden but slowly developing perceptions
and aspirations of sections of the population, especially
the young.
The existence of drug use and drug problems was officially
denied or played down in many countries, especially to the
outside world and to the general public. As a result, little
public information was available and there was little
discussion on the subject; the concept of drug use as a
social phenomenon barely existed. There were, however,
quite sophisticated regulatory and control mechanisms in
place, including registration and monitoring systems
maintained through police/psychiatric collaboration.
This was especially marked in countries whose systems
more closely resembled that of the Soviet Union. Treatment
models were based on medico-biological theories of
alcoholism, and drug addicts and drug users were usually
registered and treated (often compulsorily) in the same
in-patient psychiatric hospitals or narcology clinics as
alcoholics. Other than this, in most countries there were
very few services for drug users, and little in the way of
specific policies regarding drugs and drug-related problems
other than repression and institutionalisation. Sociological
models were strongly influenced by social–pathological
perspectives according to which drug use and dependence
were seen as ‘external’ phenomena associated with the
‘decadence’ of western countries.
These constellations of historical factors constituted
substantial barriers to change and left most countries totally
unprepared to deal with the new patterns of drug use that
started to emerge among the younger generations. Thus,
the need for prevention was rarely recognised, the level of
knowledge and awareness among both professionals and
the general population, young and old alike, was very low,
the concept of social processes such as youth subcultures in
conflict with mainstream social values was not
comprehensible (other than, perhaps, as a perverted form
of political dissent), the stigma associated with drug taking
was probably even more pronounced than in many western
countries, the treatment system was perceived as repressive,
coercive and something to be feared, and the involvement
of civil society and opportunities for non-governmental
activity were minimal.
use among groups of young people was noted in several
countries in the late 1960s, reflecting, albeit on a smaller
scale, what was happening in western countries. Patterns of
use, however, were usually quite different from those seen
in western European countries at the time — for example,
the use of cannabis, LSD, heroin and cocaine was rarely
reported, although there were exceptions.
During the 1970s and 1980s, various patterns of drug use
developed, although the extent of use is not clear. The drugs
involved were largely domestically manufactured
pharmaceutical products such as medicines containing
codeine or morphine derivatives, barbiturates,
benzodiazepines or other sedative-type drugs, e.g.
glutethimide, anti-Parkinsonian drugs or central nervous
system stimulants. Often, these medicines were combined
with alcohol. And in some countries, such as the Baltic
States, Bulgaria, Hungary and Poland, traditional use of
locally grown drugs such as opium poppy preparations
continued. In other countries, for example Czechoslovakia,
Hungary and Romania, solvent misuse was reported, mostly
among adolescents. Although cannabis grows in several
countries, it is not clear if and how widely it was used
during the 1970s and 1980s.
From the end of the 1970s, changes were observed in some
countries, including increases in (non-medical) drug
injecting. In Poland, the use of home-made ‘Polish heroin’
or ‘kompot’ emerged among young people, and
the number of addicts in Warsaw and some other cities
grew rapidly during the early 1980s before appearing to
stabilise. In Czechoslovakia (mainly the Czech part), the use
of illicitly manufactured opiates (‘Braun’) and
methylamphetamine (‘Pervitin’) expanded over the course of
the 1980s, while in Hungary there were reports of the use
of ‘poppy tea’ by young people, and also of increasing use
of glutethimide and codeine. The use of cannabis, as well
as of heroin, increased in parts of Yugoslavia in the early
1980s, probably partly because of its position on the
‘Balkan’ heroin route and partly because of its open
borders and relatively extensive contact with western
countries. In view of the tourist trade and its proximity to
Italy, it is likely that this phenomenon was also taking place
on the Adriatic coast, including in Slovenia.
These changes were in part influenced by the changes in
youth culture, which included the emergence of the drug
phenomenon, that were occurring in the late 1960s and
early 1970s in western countries. Thus, the student protests
of 1968 were echoed in some east European cities, and
demand for ‘forbidden’ cultural commodities enjoyed by
young people in the west (rock music, denim jeans, long
hair) entered into the consciousness of a new, youthful 
14
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During the 1980s, this situation slowly started to change
in some countries, for example Czechoslovakia, Hungary,
Poland and Slovenia. This was probably in part because
these countries were (relatively) more developed, both in
economic terms and in terms of greater cultural and
political independence from the Soviet system. For example,
the late 1980s saw increased references to drugs in films
and music. Also, professionals from these countries enjoyed
greater contact with colleagues in the international arena,
thus opening the way towards recognition and analysis of
the emerging drugs phenomenon from a different
perspective. The first formal policy response to the
emerging drug phenomenon occurred in Poland (in the
form of the 1985 law on drug abuse prevention, which
helped to stimulate prevention and treatment services,
including those supplied by non-governmental
organisations), and prevention programmes were instituted
in some other countries, such as Hungary. In general,
however, significant developments in policy did not take
place until the 1990s.
Key themes from the 1990s
The main developments in the drug situation and responses
over the 1990s are described later in this chapter. Several
key themes can be identified that were of particular
relevance to these developments and to future challenges.
Information, drug monitoring and research
The lack of reliable data, in the context of uncertainty and
anxiety about what to do in an apparently rapidly changing
situation, meant that the scale and nature of drug
phenomena were either exaggerated or denied. Further, the
lack of a conceptual framework for making sense of the data
that did exist meant that these changes were often
misunderstood. For example, in the early 1990s, confusion
about the significance of drug seizure indicators led to the
interpretation that interceptions of large quantities of heroin,
cocaine or cannabis on the trafficking routes through the
Balkans and up to western Europe reflected increased
consumption of those drugs in the countries concerned.
While trafficking routes can pose a risk in terms of spillage
into, and stimulation of, local markets, the principal patterns
of domestic consumption were at the time still dominated by
pre-existing drug use patterns. The result was that attention
was mainly focused on external factors (repressing the
traffic) rather than on analysing and responding to actual
patterns of consumption and internal factors (such as the
social situation and the expectations and perceptions of
young people) that were stimulating demand.
Data collection, monitoring and research developed
throughout the 1990s, initially through a training programme
in epidemiology organised by the Pompidou Group of the
Council of Europe and through the participation of many
countries in the Pompidou multicity study. The development
of epidemiological monitoring systems was subsequently
reinforced through the drug information systems (DIS) project,
which was part of the Phare multi-beneficiary drugs
programme of the European Commission, and now continues
under the aegis of the EMCDDA as part of the EU accession
process. Many countries also participate in the European
school survey project (ESPAD).
In parallel with work on indicators and statistical
information systems, a project conducted jointly by the then
United Nations drug control programme (UNDCP), now the
UNODC, and the Pompidou Group stimulated the
development of qualitative research on drug use in the
region. The resulting publication, Nine studies of emerging
drug problems (UNDCP/Pompidou Group, 2001), is a
good example of how qualitative research can offer
paradigms for analysis and interpretation that help to
understand what data mean in a way that is useful for
identifying problems and designing relevant interventions.
Privatisation and the impact of market philosophy
The economic changes of the 1990s had a major impact on
social protection measures and on the delivery of medical
care and treatment. In many countries, various forms of
insurance replaced universal State provision, leading to
major changes in treatment provision as well as to
increases in inequality regarding access to health and
social services. Poorer groups, including the newly
unemployed, were particularly vulnerable, and this,
together with a drop in living standards, led to increases in
morbidity and mortality. In a broader sense, increased
economic differences, resulting from the emergence of a
nouveau riche group in parallel with others experiencing
debilitating poverty for the first time, further widened the
material and psychological gap between included and
excluded sections of the population.
A second area where new market ideologies had an impact
on the drug situation was privatisation and deregulation of
the pharmaceutical industry, for example in the Czech
Republic, Hungary, Latvia, Poland and Slovakia. This led, in
the short term at least, to increased diversion of
psychoactive medicaments into the non-medical drugs
market and, in some cases, to covert manufacture of drugs
such as amphetamines in previously State-owned factories.
A third effect was that opening of borders and
transformation of local currencies into convertible currencies
meant that the formerly communist countries became part of
the western capitalist economy, with all the elements of free
15
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structures and mechanisms based on a broad consensus to
begin to emerge.
Influence of international interests
In parallel with the internal processes taking place in the
CEECs following 1989, the region became the focus of
increased attention from a wide range of international
organisations and other external interest groups. These
included international organisations such as the European
Commission, the UNDCP (now the UNODC), the WHO,
Unaids, Interpol, the Pompidou Group as well as NGOs
such as the Lindesmith Centre of the Open Society Institute,
the Nordic Council and the ECAD city network. In addition,
the region was the focus of bilateral interventions, usually
in the form of aid from national governments, including
those of EU Member States and the USA. All these groups
brought with them a variety of agendas for the drugs field
that were not necessarily compatible. Some were concerned
with ‘modernising’ legislation in line with Western
requirements, while others sought to bring alternative
ideological concepts of how to respond to drugs. Some
were more concerned with organised crime, border control
and drug trafficking, while others focused on health and
social aspects or on monitoring, research and data
collection. Western companies, including those with
interests in the tobacco, alcohol and pharmaceutical
industries, also saw important opportunities in the newly
opened markets. As of 1997, the role of the European
Commission shifted from providing technical assistance
through the Phare regional programme on drugs towards
promoting the Community acquis and harmonisation with
EU standards as part of the accession process.
Differences between countries
There were, and still are, important differences between the
CEECs regarding both the drug situation and their policy
developments and responses. These reflect partly national,
historical, cultural and institutional developments and partly
the balance of external influences (geopolitical, market,
impact of international pressures). This makes it difficult to
generalise across all the countries, and the broad trends
outlined below should be read in conjunction with the more
differentiated information presented in subsequent chapters
and also in the 2002 report on the drug situation in the
candidate CEECs (EMCDDA, 2002a).
There do appear to be some subregional differences.
Independence came later to the Baltic States, and it seems
that the development of new drug use patterns and of drug
policies and responses is also taking place somewhat later
there than in other countries, although there are also
important differences between the three countries. In the
Balkan subregion, Bulgaria, and even more so Romania,
trade and extended markets that this implied. It is not
surprising that illegal drug markets, while retaining some of
their local characteristics, also tended to converge and
resemble more closely the patterns of supply and demand
observed in western countries.
The shift towards a market philosophy was also
accompanied by the development of more consumer-
oriented and individualistic perspectives, especially among
younger and more urban sections of the population. It
would be surprising if these changes in consciousness did
not play an important role in influencing the evolution of
lifestyles and consumption patterns among young people,
including consumption of drugs such as cannabis,
amphetamines, ecstasy or cocaine, as well as alcohol. It
would also be surprising if the use of drugs such as heroin,
or cheaper alternatives such as sedatives, solvents and/or
combinations of these with alcohol, did not also increase
among more vulnerable groups or those who see
themselves as marginalised from the wider process of social
change.
Finally, one effect of a reduction in the power of the central
States was a growth in the non-governmental sector.
This process has been uneven — non-governmental
organisations (NGOs) evolved earlier and play a more
extensive role in the Czech Republic, Hungary, Poland and
Slovenia than in other countries — but in all countries
NGOs are increasingly seeking to meet needs arising out of
newly recognised social phenomena, such as drug use, that
State institutions appear to be ill-equipped to tackle.
Tensions in policy-making and coordination
The rapid political and economic changes taking place in
central and eastern Europe sparked a variety of power
struggles not only at a political level but also within and
between administrations and institutions. As drugs had not
been seen as an important issue in most countries, the field
was not well developed and was often dominated by a
small number of individuals or by one institution. Increasing
recognition of the drugs phenomenon and exposure to new
ideas and concepts, as well as increased possibilities for
involvement in European and international projects,
attracted new professionals and institutions into the field.
This, in turn, often led to both tensions and competition for
control and resources between old and new bodies and
between national and local organisations, but also between
health and control and interdiction-oriented perspectives
and, frequently, regarding the underlying philosophical
approach to drugs. Thus, it is perhaps not surprising that
the development of policies, legislation and coordination
mechanisms in the 1990s was a contentious and often
faltering process and that it has taken time for stable
16
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are economically poorer than their central European
neighbours, and structures and responses for dealing with
drug problems appear to be less developed. As noted
above, the countries of central Europe appear more similar
to their western neighbours not only for historical reasons
and because of the degree of contact they have enjoyed
with the west over the past two decades, but also on
account of their level of economic and social development.
In most countries, however, drugs, although perceived as a
threat, remain a relatively low political priority.
Thematic analysis 
of situation and responses
This section broadly follows the structure of the EU drug
strategy targets. The underlying question for each theme is:
How far are developments in responses adequate and
appropriate to the situation regarding current trends in
drug use and its consequences? Where possible and useful,
comparisons are made with the global EU picture. This
leads to identification of key challenges for the future.
Drug use, vulnerability, 
prevention and early intervention
Drug use
Consistent and comparable data on drug use in the general
population do not exist for many countries, so it is possible
to give only a broad descriptive overview. More data exist
for the school population, but these do not cover non-school
groups and older youths who have left school. A further
limitation is a tendency to report lifetime prevalence as an
indicator of trends in drug use, whereas in fact this is a
cumulative measure that includes drug use that may have
occurred many years ago (see EMCDDA, 2002e). A more
appropriate measure of trends in drug use is current or
recent use (e.g. last 30 days or last 12 months), but these
data are not always available.
Drug use trends and patterns in the general population,
especially young people
Trends over the early 1990s were mostly characterised by a
continued evolution of pre-existing national and cultural
patterns of drug use, with growing indications of the
appearance of ‘western’ drugs (cannabis, heroin, LSD,
cocaine) in some countries. For example, in Bulgaria, the
Czech Republic, Hungary and Slovakia, the non-medical use
of medicaments containing sedative-type compounds (often
combined with alcohol) continued to predominate among
young people. The use of codeine derivatives increased in
the Czech Republic and Hungary, while use of various
domestically produced poppy preparations containing
opiates became more common in the Baltic States, Bulgaria
and Hungary and, after a pause in the late 1980s,
increased again in Poland. The misuse of solvents by
marginalised adolescents, street children and Romany
children was important in Bulgaria, Romania, the Czech
Republic and Slovakia (and also in the last two countries
among older youths and students) as well as in Hungary,
albeit at a lower level than previously. The use of ‘Pervitin’
continued to increase in the Czech Republic, and there was
also some increase in amphetamine use in Poland and
perhaps also in Bulgaria.
Imported heroin started to show up in the early 1990s in
Bulgaria and, to a greater extent, in Slovenia (as well as in
other parts of the former Yugoslavia), and also in Hungary,
the Czech Republic and Slovakia. This accelerated in the
mid-1990s in central Europe and Bulgaria, and somewhat
later in Romania (although the picture is less clear). In the
Baltic States, heroin use did not become significant until the
second half of the 1990s, but it then increased rapidly from
1997–98 onwards, replacing domestically produced
opiates. In Poland, too, a second ‘wave’ of new heroin
users was seen from 1997 (smoking rather than injecting).
By the end of the decade, heroin was the main ‘problem
drug’ in all countries except the Czech Republic, where
Pervitin was still predominant.
Cannabis use started to increase among young people in
central Europe (Hungary, the Czech Republic, Poland,
Slovakia and Slovenia), but in the early 1990s only
Slovenia reported relatively high levels of use. The rate of
increase rose from the mid-1990s, and by the end of the
decade, in some but not all countries, the proportion of
young people who had tried cannabis at some point in their
life appeared to be approaching that found in many EU
Member States. Among younger age groups, ESPAD school
surveys found that in most countries both lifetime and last
30 days prevalence of cannabis use by 16-year-old
schoolchildren doubled between 1995 and 1999 (Figure 1).
In the early 1990s, use of LSD, amphetamines and
occasionally cocaine in nightspots was reported among
a small, fashionable crowd. Subsequently, from the mid
to the late 1990s, there was some increase among youth
groups, especially in cities, of LSD, ecstasy and
amphetamine use.
Thus, over the second half of the 1990s, while previous
drug use patterns continued, there was evidence of a move
towards a western pattern of drug use, notably cannabis
use, among a cross-section of young people, of the use of
heroin in various groups but increasingly among more
marginalised communities, and of the use of so-called
‘party drugs’ (ecstasy and LSD), primarily among more
affluent, city youth; cocaine use was still relatively rare.
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qualitative or impressionistic information suggesting
continuing increases is available. In all countries, the
pattern of use is dominated by experimental or occasional
use, mainly of cannabis. At the same time, these studies
suggest an increased intensity of use by those (the minority)
who continue to use. In other reports, diffusion of drug use
from cities to smaller towns and rural communities is
described. The 2003 ESPAD study should help cast light on
Current trends are hard to assess, as very recent data are
lacking in most countries. There are tentative indications
from some studies that in some countries the increase in
drug use may have started to stabilise in the early 2000s,
especially in major cities, where prevalence levels are
usually several times higher than in rural areas (e.g. in
Warsaw as well as in cities in Hungary and the Czech
Republic). In other countries, data are rare or only limited
18
Figure 1: Lifetime prevalence of use of cannabis, other illicit drugs, tranquillisers or sedatives among school students aged 15 or 16 years
in the CEECs and the EU and Norway, 1995–99 (%)
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trends among 16-year-old schoolchildren, although the
results will not be available until 2004 and, as noted
above, will not reflect trends in older groups of young
people, up to the age of 25 or so, in whom drug use
prevalence is likely to be higher.
While the convergence of drug use patterns with those seen
in western Europe is not surprising, there remain certain
aspects that may require specific attention in these
countries. These include the continuing high level of use of
pharmaceutical drugs (especially sedatives and
tranquillisers) for non-medical purposes in some countries
and the increased and often high level of use of drugs other
than cannabis, especially heroin and/or amphetamines,
among young populations in many countries.
Context, risk and vulnerability
It is apparent from the account given above that the
changes in drug use observed in the CEECs in the 1990s
did not suddenly appear out of the blue but rather were a
manifestation of social trends in consciousness and
behaviour that were already under way, especially among
younger sections of the population, and most particularly in
the larger cities. The rapid political and economic changes
following 1989 brought new elements that fed into the
pattern of youth opportunities, lifestyles and behaviours and
helped accelerate the rate of change.
This analysis suggests that the driving forces underlying
increases in drug use were predominantly demand related
rather than an increased supply of drugs. It is, however,
true that the opening up to western markets increased
exposure to ‘western’ substances, including western brands
of alcohol and cigarettes, and that over the decade this
exposure played an important role in shaping the
characteristics of the demand for drugs (and alcohol),
which, as a result, has become more similar to the picture
found in the current EU countries, especially as regards
cannabis, ecstasy, LSD and heroin use. As in any situation,
the demand for drugs is influenced by a complex interplay
of different elements — pharmacological, individual, social
and economic. However, it is important to distinguish
factors that influence the level and pattern of drug demand
in general from factors associated with increased
vulnerability to riskier or potentially problematic patterns of
use, as they are often different.
Factors affecting the demand for drugs
A wide range of explanations and risk factors for drug use
can be found in the scientific and not so scientific literature.
Many of these are not specific to the CEECs, for example,
explanations based on the pharmacological properties of
different drugs, curiosity, peer pressure or risk-taking are
relevant across many situations. The comments below focus
on selected perspectives that may help understand the
developments in the demand for drugs in these countries
at this point in time.
In many CEECs, drug use increasingly may be coming to be
perceived, especially among some sections of urban youth,
as normative (drug use as part of modern lifestyles) rather
than pathological. The reasons for this are not hard to see
— exposure to perceived western ideals and lifestyles,
including images of drugs in music, literature and
advertising, and increased freedom to express them, may
be accompanied by an increased willingness to experiment
with drugs. This process is facilitated by increased mobility,
travel and tourism, as well as by increased communication
through the Internet and by increased commercialisation
and the global promotion of youth culture and consumer
products such as music, fashion or computer games. 
Pre-existing patterns of drug use associated with previous
lifestyles and recreational activities are also changing in
this process but are likely to be adapted and incorporated
into new patterns of consumption (especially of alcohol)
rather than abandoned altogether.
The rate and nature of social change are also of particular
relevance. Such change includes a weakening of traditional
social ties, changes in family relationships and in
relationships with authority, generational conflict and the
search for identity via new associations. This process is not
limited to particular groups or strata. Children from socially
integrated backgrounds as much as any other react against
their parents’ generation and values and seek status
through the chic and the cool.
Economic factors are also likely to affect the patterns of
drug use emerging in this process of change, although
local variations and lack of research make generalisations
unwise. Thus, the relationship between drug (and alcohol)
use and socioeconomic status is not simple. In some
settings, use is higher among the integrated, better-off
sections of the population, perhaps reflecting higher
disposable incomes available for spending on consumption.
In other settings, higher levels of use are also found
among more marginal or lower-income groups.
The availability of drugs also reflects a range of domestic,
international and geopolitical factors (see below) and is
a further important factor in influencing the pattern of drug
use in the countries concerned.
Vulnerability to high-risk drug use
Much drug use, as in western countries, is experimental or
of limited duration and intensity. Mostly, it does not result in
problems such as dependence, illness or drug-related
criminal activity. However, some groups and individuals are
more vulnerable. Many factors associated with vulnerability
19
Annual report 2003: the state of the drugs problem in the acceding and candidate countries to the European Union
increase rather than diminish risks, for example through
labelling, stigmatisation or school exclusion.
In summary, in the CEECs four broad groups vulnerable
to drug use can be delineated:
• young people in economically depressed areas
and marginalised groups whose future options are
limited — these groups and communities are most
at risk of long-term, structurally embedded patterns
of problem drug use;
• children from dysfunctional families regardless of
economic status (i.e. including those from socially
integrated and affluent backgrounds), especially those
whose parents are heavy users of alcohol or prescription
drugs or who have other social or behavioural problems,
such as being exposed to conflict or rejection;
• young people, including the socially integrated, who
are frequent users of various drugs, including alcohol,
cannabis, amphetamines and ecstasy, within recreational
settings but whose knowledge of possible consequences
and risks is low and where professional experience of
dealing with drug problems may be limited;
• successful entrepreneurs and others (and their children)
with access to money and western commodities,
including drugs such as heroin or cocaine, who are
preoccupied with western sophistication and
conspicuous consumption, as well as experiencing
stress, frequent travel, etc.
Prevention and early intervention
Prevention strategies and interventions
The 2002 report on the drug situation in the candidate
CEECs (EMCDDA, 2002a) describes recent developments
and the range of approaches to prevention and early
intervention found in the various countries. From a long-
term perspective, it is important to remember that the
concept of a comprehensive and systematic drug prevention
policy is relatively recent in most of the CEECs. Although
Poland passed a law on drug abuse prevention in 1985, by
the mid-1990s only Hungary and the Czech Republic had
set up specific prevention strategies at national level. Since
then, these and other countries have revised or developed
new prevention strategies. However, in practice, it is often
difficult to know to what extent and in what manner
programmes referred to in national reports or policy
documents have been put into practice.
As in EU Member States, school-based activities are the
most common approach reported. In the late 1980s, the
greatest investment in school-based programmes was in
are not specific to the CEECs, although knowledge of them
could be useful in targeting interventions. Examples include
individual factors such as depression, high anxiety and
mental illness, as well as family circumstances such as
rejection, sexual abuse and alcoholism. However, children
ignored by parents preoccupied with economic survival or
advancement may also be at higher risk, even where there
are no overt problems or indications of dysfunction.
Vulnerability factors for high-risk drug use in the CEECs
have been accentuated by rapid social and economic
change such as a reduction in living standards, industrial
decline, increasing unemployment (especially among young
people) and limited options for the future. An increase in
the rich–poor divide, the consequent gap between
expectations and opportunities, the sense of alienation
arising from the process of rapid social change and
reduced access to health and social care are all likely to
increase vulnerability. Marginalisation, social exclusion and
stigmatisation appear to be particularly problematic among
the Russian-speaking minorities in the Baltic region (Estonia
and Latvia), Romany youth across much of central Europe
and the Balkans (Bulgaria, the Czech Republic, Hungary,
Romania, Slovakia), street children in Romania, poorer
groups in all countries with lower education, lack of
qualifications and experience of school exclusion, migrants,
including those associated with rural–urban shift, and
immigrants from the former Soviet States.
Personal or family factors affect the likelihood of high-risk
drug use at an individual level, while social and economic
processes render some communities or groups more
vulnerable than others. The increased availability of drugs
such as heroin in conjunction with these factors also plays a
role in shaping drug choice and patterns of use, although,
as suggested above, availability is not by itself the
underlying causal factor. However, a broader question of
vulnerability concerns the level of knowledge and
awareness about drug use among the population, and
especially among young people who are already using
cannabis, amphetamines, ecstasy or other drugs in
recreational contexts. In western countries, where drugs and
drug use have for some time been part of the environment
in which young people grow up, a greater awareness of
drugs has developed and informal social mechanisms of
information dissemination and self-regulation have evolved,
especially among groups more involved in drug use. These
may help to reduce some of the risks. In parallel, wider
society, social institutions and professionals have experience
of responding to drug-taking among young people. In
contrast, in countries where drugs are a more recent
phenomenon, risky patterns of use may be more likely to
lead to inappropriate reactions that may inadvertently
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Hungary (although, even so, most pupils were not covered),
although Poland had introduced the issue of drugs into the
school curriculum under the 1985 law on drug abuse
prevention, and Bulgaria started to train teachers about
drugs in 1988. During the early 1990s, a variety of model
programmes and local activities were implemented in these
and other countries. Several points can be made about the
situation up to the mid-1990s.
In many cases, drug prevention was largely information
based rather than pedagogic, although this did not exclude
teachers from making moral assertions about the
undesirability of using drugs. At that time, it was common
practice to translate prevention materials that had been
developed for use in the USA or in west European countries
and to use them without revising them to reflect local
circumstances and needs. Implementation of programmes
was usually informal, and frequently relied on training
teachers, in the hope that this would translate into effective
classroom education, rather than on developing more holistic
approaches, although in some countries selected schools took
part in the WHO health-promoting schools network.
Since then, some countries have started to elaborate more
holistic and pedagogically based school programmes, often
integrated within a wider perspective of health education
and personal decision-making (EMCDDA, 2002b). However,
evaluation of the manner and extent of implementation
or the impact of such programmes is still rare.
There is little information on the evolution and application
of mass media campaigns on drugs, although campaigns
have been carried out in some of the CEECs, often linked
to events such as the European Drug Prevention Week. It
appears that there is considerable potential for improving
how drugs are dealt with by the media in terms of
providing more informed and discriminating coverage
and promoting more thoughtful, less moralistic analyses.
In recent years, there has been an impressive development
of a variety of community-based prevention activities in
some countries. These are mostly based at local or regional
level and are implemented through specific projects, NGOs
or decentralised networks of local drug coordinators.
Some are targeted at specific groups, such as prisoners or
recreational drug users, while others are more concerned
with enhancing prevention through the provision of
information and training for local professionals, and others
still aim at promoting a range of activities for young
people. Projects funded by the Phare drug demand
reduction programme are also promoting increased
networking and information exchange between NGOs
working on various aspects of prevention and risk
reduction in different countries.
Issues and challenges
Drug use levels are becoming more similar to those in
western European countries, and patterns of use often
reflect very similar underlying factors, even though the
specific historical and contextual elements have influenced
both the local processes and the characteristics of the
vulnerable populations and situations. The challenge is to
acknowledge the reality of drug use and respond to it in a
balanced way that neither denies nor exaggerates the risks
and sets realistic goals about what can be achieved.
It is also important to adopt approaches based on an
appreciation of the social and cultural dimensions that
mould patterns of drug use and on an understanding of
drug use as part of a broader lifestyle and consumer-
oriented phenomenon in which some people and groups
are more likely than others to experience problems. This
contrasts with perspectives in which drug use is seen as
external and pathological. This, in turn, implies a
differentiated pedagogic and public health approach to
the concepts of risk and vulnerability.
The most effective approach depends in part on the drugs
involved and patterns of use. Cannabis is the most widely
used illicit drug, but most users do not experience health or
social problems, and the individual and social costs
associated with cannabis use are relatively low in
comparison with some other types of drugs, although some
more vulnerable young people do encounter difficulties.
Further, data show that the prevalence of current (last
30 days) or recent (last 12 months) use of cannabis is
several times lower than lifetime prevalence, indicating that
continuing, regular use of cannabis is relatively uncommon,
even in so-called high-prevalence areas. Recreational use
of ‘party’ drugs such as ecstasy or amphetamines may
carry higher risks and potential costs, especially when part
of a pattern of more frequent multiple drug consumption,
although, as with cannabis, most people who use these
drugs do so experimentally or intermittently rather than
intensively. In contrast, major health and social costs arise
from dependence on opiates, especially heroin, and
especially when injected. The high prevalence of drug
injecting in many of the CEECs means that preventing
opiate use and drug injecting and reducing the damage
that they cause is a substantial challenge.
Finally, the use of legal substances, especially alcohol and
tobacco, is more prevalent and frequent than the use of any
illegal drug and is more likely to continue into adulthood.
The (non-medical) use of medicines, especially tranquillisers
and sedatives, is also relatively high in the CEECs.
These common themes apart, there are also important local
differences within and between countries not only in
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Problem drug use and its consequences, 
treatment and harm reduction
Problem drug use
Prevalence
Reliable estimates of the prevalence of problem drug use
exist for only a few CEECs. In the case of some other
countries, ‘informed estimates’ are available, but it is not
clear how reliable these are, or if they are based on
comparable criteria.
For the purpose of estimating prevalence, ‘problem drug
use’ is operationally defined by the EMCDDA as injecting
drug use or long-duration/regular use of opiates, cocaine
and/or amphetamines. Although useful for prevalence
estimation, this definition is narrower than some clinical
definitions, which also include heavy use of drugs such as
cannabis or sedatives.
From available data, and subject to the reservations
expressed above, it appears that the level of problem drug
use in the CEECs is approaching, and in some cases has
surpassed, levels reported for EU Member States. The 2002
report on the drug situation in the candidate CEECs
(EMCDDA, 2002a) estimated the proportion of problem
drug users among the population aged 15 to 64 to be over
1 % in Estonia and Latvia, around 0.5 % (the EU average)
in Bulgaria, the Czech Republic and Slovenia, and around
0.25 % in Poland (lower than the EU average but based on
older data). Rapid increases in new cases of heroin
smoking reflected in treatment data over recent years
suggest that the estimate for Poland would now be higher,
while a new estimate for Slovenia implies a rate of problem
drug use of over 1 %. No estimates are available for
Hungary, Lithuania, Romania or Slovakia.
Most increases over the 1990s, and especially since the
mid-1990s, were due to heroin, which is now the main
drug involved in every country except the Czech Republic,
where Pervitin use still predominates. Many of these
increases have been accompanied by increases in injecting
drug use, although smoking heroin is common in Poland
and is also reported among young users in some other
countries.
It is harder to be sure about current trends, as very recent
data are often not available. In the Czech Republic,
Hungary, Slovakia, Slovenia and perhaps Bulgaria,
it appears that the overall level of problem drug use may
be stabilising. In Poland, the Baltic States and Romania,
problem drug use (in particular heroin use) seems to
be increasing.
Current trends in the problem use of drugs other than
heroin are variable. In most countries, use of locally
traditions and patterns of drug and alcohol use, but also in
the constellations of risk factors that are found. Responses
need to take account of local circumstances such as
demographic and cultural profile, socioeconomic situation
or level of crime. Similarly, institutions, structures, services
and networks have often developed their own local styles of
functioning and inter-relating. While efforts at national level
to develop and implement pedagogic approaches to
prevention within the broader framework of school-based
health education programmes are showing progress in
some countries, a greater challenge is to assess needs,
identify priorities and develop flexible responses that are
appropriate to local circumstances.
Further, while preventative efforts are often focused on
school-based interventions, it is essential to remember that
high-risk patterns of drug use are observed among some
not-at-school groups and that higher prevalence rates of
drug use are found among older young people, often after
they have left school. This is especially true of drugs such as
heroin, amphetamines and cocaine. It is therefore important
to stimulate and build on community-level actions that are
broader and more comprehensive. A number of interesting
projects and programmes are already under way in some
countries, but they need to be expanded and more widely
implemented.
A major challenge here is to identify appropriate strategies
and responses and to build a consensus (social solidarity)
to support a comprehensive and integrated approach based
on reliable information. This approach would include
addressing issues such as attitudes and levels of awareness
about drugs and drug problems among both the public and
professionals, how to implement relevant information and
training policies, how to develop responses that are
inclusive rather than stigmatising and excluding, how to
coordinate effectively and how to involve civic society more
constructively. The question of the role of the media is also
crucial here.
A final challenge is to improve the quality of data
collection and research so as to be able to base policies
and responses on a sounder foundation of evidence. This
should cover quantitative and qualitative methods to
monitor and understand drug use patterns and trends
among youths, as well as evaluation of the implementation
and effectiveness of the various preventative measures.
Although implementation of indicators for monitoring
prevalence and trends is improving, there is still much to
be done in many countries, and the level of evaluation is
still very low. In the meantime, there is an existing and
growing body of knowledge and research-based evidence
that could be very helpful for developing policies,
strategies and interventions.
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produced opiates is diminishing. Treatment demand data
reflect some problem amphetamine use (e.g. around 10 %
of treatment demand) in the Baltic region, Slovakia and
Hungary, but not in the Czech Republic. However, an
increase in problem amphetamine use is reported only from
Estonia. Cocaine use is uncommon among treatment
populations. Sedative users (in older groups) and solvent
users (in young groups) continue to account for a significant
minority of drug users entering treatment in a few countries,
but it is likely that solvent use is under-reported. Cannabis
is significant (over 10 %) in treatment data in some
countries (Czech Republic, Hungary, Poland, Slovakia and
Slovenia), but only in Hungary and the Czech Republic are
increasing trends reported.
Within countries, problem drug use typically shows a very
uneven geographical distribution. Prevalence is often
considerably higher in regions with a high level of social
problems in general and also in big cities, although this
may in part reflect a temporal trend whereby increased
drug use occurs first in the cities and subsequently diffuses
to other parts of the country and to smaller towns.
The average age of problem drug users entering treatment
for the first time is lower in the CEECs (early 20s) than in
the EU Member States (late 20s), reflecting the more recent
evolution of heroin use. In most countries for which data
are available over several years, the age of people entering
treatment is no longer falling and the proportion of first
treatment demands as a proportion of the total demand is
tending to decrease, consistent with a slowing or
stabilisation in the rate of growth; however, there are
exceptions, for example Poland.
Implications for treatment and harm reduction responses
Some of the factors affecting the susceptibility of high-risk
drug use to develop into problem use were described
earlier in this chapter. These include individual and family
circumstances as well as social and economic factors and
the supply and availability of drugs such as heroin.
Although all social and economic sectors are to some extent
affected, problem drug use tends to be concentrated in
more marginal groups, for example among Russian
speakers in parts of the Baltic region, Romany youth in the
Balkans and central Europe, and more generally, although
not exclusively, among young people living in more
economically depressed communities or situations of social
disruption and uncertainty. This means that delivering
relevant treatment services and interventions to reduce the
harmful consequences of problem drug use requires special
efforts if the gaps arising from exclusion and stigmatisation
are to be bridged and if the barriers of ignorance,
suspicion of official institutions and reduced access to
services are to be overcome. This, in turn, implies a
proactive, positive and culturally sensitive approach to
promoting human rights, building trust, disseminating
reliable and relevant information, training and developing
accessible services.
Although increasing trends in problem drug use show signs
of slowing or levelling off in several countries, the high
prevalence levels described above imply a substantial need
for treatment and care over the coming decade(s). In
particular, the high, and in some countries increasing, level
of drug injecting means that radical steps are needed to
prevent or reduce serious health consequences such as
infectious diseases and deaths. Further, the tendency for
drug use to diffuse from large cities to other areas suggests
that services and training are needed country-wide. Taken
together, these findings emphasise the importance of long-
term strategic planning and development of treatment, care
and harm reduction responses.
Although heroin is the main drug involved, other significant
patterns of problem drug use demand attention, including
heavy use of amphetamines, multiple drug use with
sedatives and/or alcohol and, in some countries, solvents.
Qualitative research involving users of other drugs, e.g.
amphetamine users in Poland or the Czech Republic,
suggests that, depending on context, their perceptions and
needs may differ substantially from those of heroin users.
This underlines the importance of local needs assessment
and of research that involves clients and potential clients of
the services.
Treatment responses
Types and extent of drug treatment services
The 2002 report on the drug situation in the candidate
CEECs (EMCDDA, 2002a) provides more details on
treatment services. Traditionally, treatment consisted of
inpatient detoxification, often compulsory, in psychiatric
hospitals or narcology clinics. Known users were subject to
registration, monitoring and control by the authorities,
including the police. Only in Poland were non-
governmental residential therapeutic facilities available for
drug users. After 1989, the legacy of the ‘narcology’
system was widespread mistrust of State-based psychiatric
treatment. By the mid-1990s, this system was rapidly
breaking down under pressure of health care reforms —
privatisation and insurance-based schemes introduced
profit-driven provision, and new systems evolved, although
they were often staffed by the same people, so individual
attitudes towards addicts did not necessarily change so
quickly.
In many of the CEECs (e.g. Bulgaria, the Czech Republic,
Hungary, Slovakia and Slovenia), outpatient drug treatment
services developed during the 1990s, usually as part of the
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• outpatient services offering structured programmes
and individual and family therapy;
• methadone programmes offering maintenance as well
as detoxification;
• inpatient detoxification and longer-term therapeutic
communities;
• rehabilitation programmes, including education,
vocational training and relapse prevention;
• user support and self-help groups;
• targeted services (e.g. women, street children, members
of ethnic minorities, migrants, prisoners);
• training of professionals and health service
administrators, in particular aiming to broaden the
understanding of the issue and improve professional
standards.
If treatment systems are to be able to cope with the long-
term consequences of the high prevalence levels currently
observed in many countries, some important challenges
arise.
The first major challenge is to broaden the range of
treatment options available and improve access to care.
This process has started but needs reinforcing. Care
delivery models vary between countries, but civil society
and NGOs can play an important role in this area, and
their involvement may be particularly appropriate for
broadening the range of treatment options available to
countries. A critical need exists to expand substantially the
public health system and attached to psychiatric
departments, but in a few cases also in the private sector. In
other countries, treatment still consists primarily of inpatient
detoxification. In a very few countries, primary health care
providers are also involved, but in most they play little part.
Substitution treatment, in particular with methadone, has
been slow to develop. The first (experimental) methadone
programme started in Slovenia in 1990, to be followed by
others in the Czech Republic (1992) and Poland (1993).
In other countries, the first methadone programmes date
from 1995 or later, although by 2001 all countries had
introduced at least one. However, except in Slovenia, the
number of programmes is limited and coverage remains
very low indeed. In Slovenia, a nationwide network
provides methadone treatment to perhaps 20 % of the
estimated total heroin-dependent population. In all other
countries, coverage is less than 5 %, and in many countries
under 1 to 2 %. This contrasts with an average coverage of
well over 30 % in the EU Member States (Figure 2). Other
pharmacological treatments are available to a limited extent
in some countries, including naltrexone and buprenorphine,
but systematic information is not available.
NGOs’ involvement has also been slow to develop in many
countries, although in some (the Czech Republic, Hungary,
Poland and Slovenia) NGOs play an important role in
providing treatment and counselling to drug users. In
Poland, this dates back almost 20 years, and in Hungary to
the late 1980s, while in the Czech Republic and Slovenia
extensive NGO networks evolved during the 1990s. Very
recently, NGOs have started to play an important and
increasing role in some of the other countries.
Issues and challenges
It is well established that an effective treatment system for
problem drug users can produce important benefits not only
to drug users themselves and those close to them, but also
to the wider society through reducing social costs arising
from disease and crime. While some countries have made
impressive progress, a major challenge across much of
central and eastern Europe is to increase the diversity,
capacity and effectiveness of treatment services available to
problem drug users.
This is closely linked to the need for long-term strategic
planning based on the concept of a comprehensive
treatment system offering a range of treatment and care
services for a range of needs. While details depend
on national and local circumstances, a comprehensive
system may encompass:
• local, low-threshold services offering access, advice,
counselling and referral;
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Figure 2: Methadone coverage: estimated proportion of opiate-
dependent drug users in methadone treatment, 2001
Sources: Multiple sources including EU and CEEC national reports.
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capacity and coverage of treatment programmes and
ensure that appropriate treatment options are available to
meet the identified needs of different groups. Substitution
programmes, using drugs such as methadone, can play an
important role in addressing problems associated with
heroin and other opiates. Although there is resistance
among some political and professional circles, evidence
from clinical experience and scientific research indicates
that professionally managed programmes can be an
effective component of a comprehensive treatment response
to heroin dependence. Given the stigma and marginality
surrounding problem drug use, it is important to promote in
practice the concept of medical ethics and patients’ rights,
for example rights to privacy and confidentiality, access to
services and treatment choice, and more broadly to link the
development of treatment services to wider actions on social
exclusion.
It is essential to improve the quality of information on
prevalence, problems and needs in order to target treatment
services more appropriately, and to evaluate the treatment
that is provided in order to improve its effectiveness.
Health consequences
Drug-related infectious diseases
Infectious diseases such as HIV/AIDS, hepatitis B and C
and tuberculosis are among the more serious health
consequences of problem drug use, in particular drug
injecting. Chapter 3 gives more detail on prevalence and
trends in HIV and hepatitis B and C among injecting drug
users in the different countries of central and eastern
Europe.
The prevalence of HIV infection among drug injectors
remained very low throughout the 1980s and into the
1990s in all the CEECs except Poland, where an epidemic
occurred among injectors of ‘Polish heroin’ at the end of the
1980s. Otherwise, the overall picture of low prevalence
was similar to that observed in northern and central EU
countries but in contrast to high infection rates among drug
injectors in some southern EU countries.
Throughout the 1990s, and especially towards the end of
the decade, patterns of infection became more
differentiated. In Poland, the annual incidence of new
infections decreased from 1991 and remained at a stable
and relatively low level from 1995 to 2002. As a result, the
prevalence of HIV infection among injectors, although still
above 10 %, is also stable.
At the end of the 1990s, sharp increases in the prevalence
of HIV infection occurred in Estonia and Latvia, and a
slowly increasing trend in Lithuania was reported.
Neighbouring Finland also experienced a sudden outbreak
of new cases of HIV among drug injectors in 1999, but the
rate subsequently dropped to almost zero, suggesting that
the outbreak had been contained.
In all other CEECs from which data are available (not
available from Romania), the prevalence of HIV among
drug injectors remains very low.
The prevalence of HCV among injectors is high (70–80 %
or more) in the Baltic States and Bulgaria, but lower in
others (lower even than in most EU countries), although
data are not available from Poland and Romania. In some
countries, such as the Czech Republic, the rate of new
infections may be declining, whereas in others, such as
Hungary, it appears to be increasing among younger drug
injectors.
Possible explanations for differences in HIV infection 
among drug injectors
There are several possible (not mutually exclusive) reasons
for patterns and differences in HIV infection observed
among drug injectors in different countries. These include:
• levels of high-risk behaviour such as drug injecting and
sharing of injecting materials, as well as patterns of sexual
behaviour, especially among commercial sex workers;
• geographical proximity to areas of high HIV prevalence,
and the degree of mobility of and contact between high-
risk populations;
• context-specific factors such as the prevalence of drug
injecting in prisons or among socially marginalised
groups;
• level of awareness of risk and protective factors among
drug users;
• facilities for hygienic injection, including access to clean
injecting material;
• police responses to drug injecting or syringe possession;
• more broadly, the extent to which HIV prevention
policies exist and information and harm reduction
services targeted at drug injectors are in place;
• wider economic and social factors that facilitate spread
of HIV, such as poverty, exclusion and stigmatisation, as
well as the state of development of health and social
care structures, the degree of knowledge and awareness
among professionals and the level of ignorance and
fear among the general public.
A combination of most of these factors is relevant to recent
rises in the prevalence of HIV infection among drug
injectors in some Baltic States (in particular Estonia and
Latvia). Sharp increases in the availability and use of
heroin in the late 1990s were associated with high levels of
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and Slovakia with the Ukraine). However, the extent to
which there is contact between drug injectors across these
borders is not clear. Slovenia has a border with Italy, and
there has always been some cross-border contact, although
rates in Italy are now declining. In addition, heroin use and
injecting in these countries is often more prevalent in more
socially problematic areas and there are significant
marginal groups (e.g. Romany youth, street children,
prisoners) that are at higher risk.
Thus, despite the presence of a range of important risk
factors (injecting, needle sharing, proximity to areas of high
HIV prevalence, vulnerable populations), the prevalence of
reported HIV infection has remained low in these countries
(data are not available for Romania). One explanation for
this may be that Slovenia and the Czech Republic, as well
as Poland and to some extent Lithuania, were quicker in
introducing information, education and harm reduction
activities aimed at preventing transmission of infectious
diseases among drug injectors. Other countries, despite
slower or more limited responses, may be lucky in that their
drug-injecting populations were more closed or have had
relatively little contact with other groups in which HIV (and
HCV) infection is more prevalent, as there is evidence of
continuing high-risk behaviours such as sharing injecting
equipment in all countries. High rates of HCV infection in
Bulgaria and medium rates (up to 40 %) elsewhere
reinforce this point.
Mortality and drug-related deaths
Data on drug-related deaths are rather limited in most
countries and are not comparable between countries.
Where trend data are available, they indicate increases
in many countries, largely linked to increases in injection
of heroin.
If the scenario of increasing drug injecting (especially of
heroin) continues, together with widespread use of alcohol
and depressant psychoactive medicines, then substantial
increases in drug-related deaths can be expected, as
occurred in western European countries during the 1980s
and early 1990s. The limited information available points
in that direction, and improved monitoring and
development of focused interventions to reduce overdoses
should be considered.
It can be anticipated that, as has been observed in other
countries, mortality rates among problem drug-using
populations, in particular injectors, will be up to 20 times
higher than among the general population of the same age,
with the additional mortality attributable not only to
inadvertent overdoses but also to accidents, suicides, AIDS
and other infectious diseases.
injecting and equipment sharing in populations with little
prior experience of drug use and low awareness of risk,
and occurred disproportionately among more marginalised
groups, in particular the Russian-speaking community.
Geographical proximity to Russia, the Russian enclave of
Kaliningrad and Belarus, where HIV infection among drug
injectors has also shown recent dramatic increases, is a
further significant factor. High HIV prevalence is also
reported among drug users in prison, indicating an
important vector for further transmission of infection.
An increase in heroin injection in the Baltic region took
place later but perhaps more rapidly than in other
countries. Although harm reduction measures were
introduced a little earlier in Lithuania, public health
measures were slow to develop in the region. Needle
exchange was introduced relatively late in Estonia and later
still in Latvia, and the coverage of needle exchange
programmes remains low in all Baltic States. The
availability of methadone substitution treatment is also very
limited.
Although Poland also has borders with Kaliningrad and
Belarus, as well as with the Ukraine (which is also
experiencing an HIV epidemic among drug injectors), and
although a second ‘wave’ of new heroin use occurred
during the second half of the 1990s, the incidence of new
cases of HIV infection among drug users in Poland is not
increasing. This may be because the recent increase in
heroin use in Poland has mostly involved smoking rather
than injecting, but it is also possible that the experience of
the earlier epidemic of HIV among drug injectors in
Poland led to a range of responses (information,
education, harm reduction) and changes in behaviour that
helped to protect Polish drug users, and it may be that
there is little contact between Polish injectors and those
from neighbouring countries. More information is needed
to establish the relative importance of these and other
factors. However, while treatment demand data reveal
a declining trend in high-risk behaviour (i.e. equipment
sharing) by injectors over some years, recent data
indicate that there has been a large increase in needle
sharing among new heroin injectors in Warsaw,
suggesting a potential risk for increased HIV
transmission in the future.
In the other countries in the central European and Balkan
regions, drug injection increased during the 1990s, and
injection is the most common route of administration of
heroin. As in the Baltic States, sharing injecting material is
also quite common, although this risk factor has decreased
substantially in Slovenia and appears to be declining in the
Czech Republic. Several countries also have borders to the
east with areas of high HIV prevalence (Hungary, Romania
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Sharp increases in drug-related deaths received marked
media and policy attention in western countries during the
1980s and 1990s. The public impact of drug deaths in the
new Member States will depend also on other
contemporaneous political and social concerns. It should be
borne in mind that a substantial proportion of the 7 000
to 9 000 acute deaths reported each year in current EU
countries are avoidable, and the same will be the case
for the new Member States.
Harm reduction responses
In this chapter, ‘harm reduction’ refers to public health
measures taken to reduce the health and social damage
caused to individuals and communities by drug use, and
especially by problem drug use.
Debates over harm reduction have taken place in western
countries since the 1980s, mostly prompted by concern
about HIV/AIDS among drug injectors. In some, harm
reduction policies and measures date back over 20 years,
while in others they are more recent. In some cases,
resistance to the concept, and in particular to some
activities conducted as harm reduction, still continues.
However, in almost all EU countries harm reduction
(although it may not always be called as such) is now a key
element of any drug policy, and many countries have
introduced harm reduction interventions or expanded the
scale of established harm reduction interventions such as
methadone substitution programmes, syringe exchange
schemes and outreach programmes. At EU level, reducing
drug-related health damage, especially drug-related
infectious diseases and drug-related deaths, is one of the
six key objectives of the EU strategy and action plan on
drugs (2000–04), and the European Council has recently
adopted a resolution calling on Member States to
implement a range of harm reduction measures. However,
this approach remains controversial in many parts of
central and eastern Europe and, in general, harm reduction
measures have been slow to develop (Figure 3). This is not
surprising, given the historical context. Harm reduction in
the CEECs began in the 1990s as an alien concept
imported from the west, initially through the activities of the
Lindesmith Centre of the Open Society Institute, which
promoted approaches such as methadone maintenance and
needle exchange. While the projects that these institutions
funded focused on local interventions such as low-threshold
centres, information dissemination, outreach initiatives,
needle exchange schemes and condom distribution, the
wider discourse surrounding these efforts was often
dominated by ideological debate. In some countries, other
organisations were promoting training and other
programmes focusing on primary prevention or treatment,
while in the Baltic region organisations such as the
European Cities Against Drugs (ECAD) were advocating
alternative, drug-free approaches. Across central and
eastern Europe as a whole, the UNDCP was encouraging
governments to reform legislation in line with the UN
conventions. This meant that policy priorities sometimes
focused on criminalising drug use, and priority was given
to law enforcement rather than demand reduction activities.
Harm reduction approaches were also sometimes in conflict
with deeply ingrained constructions of drug use and drug
addiction held by some professional groups. As a
consequence, at times the debate became polarised,
emotional and occasionally even ill-informed, with drug
control and harm reduction measure seen as contradictory.
The result was counter-productive, hindering project
development and the implementation of public health
measures to deal with rising drug use and the consequences
of increased drug injecting.
A number of other processes that evolved over the 1990s
contributed to wider dissemination of information about harm
reduction, for example participation by central and east
European experts in international harm reduction and other
conferences, activities and projects supported by Unaids,
translation and dissemination of guidelines on outreach by
the Pompidou Group, or the EC Phare demand reduction
subproject on harm reduction, which helped stimulate
development of harm reduction policies and responses in the
Czech Republic and Slovenia. In some countries, the concept
was taken up by key professional or political figures, who put
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Figure 3: Time chart: year of introduction of the first methadone substitution programme and syringe exchange programme
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The health and social costs for both the individual and the
wider community are likely to be considerable and have an
impact for many years to come. Intervening to reduce this
potential problem is thus a clear priority for public health
policy and will require significant investment in the
development of national and local structures that are
matched in scope and coverage to the nature and
dimensions of the public health problem.
Implementation of effective harm reduction measures
requires a national comprehensive strategy and
commitment to put it into practice. Although there are
interesting local developments in many countries, so far
the Czech Republic and Slovenia seem to be most
advanced in terms of national programmes, although
progress is reported in other countries, such as Poland
and Lithuania, and steps in this direction are being taken
in Hungary and Slovakia. Measures to reduce drug-
related health damage appear to be particularly urgently
required in Estonia and Latvia. Implementation of
strategies to prevent drug-related infectious diseases
seems also to be urgent in Bulgaria and especially
Romania for a combination of reasons that include a high
level of high-risk behaviour among drug users, a relative
lack of knowledge of the consequences of drug use, the
existence of marginalised communities, their relatively
weak economic situation and, in the case of Romania,
a long border with the Ukraine.
In concrete terms, improving prevention of drug-related
infectious diseases and deaths presents challenges at
several levels, including:
• changing attitudes and increasing knowledge among
the general population, politicians and professionals
and providing increased training for professionals;
• the provision of information, education and outreach
initiatives among drug injectors and high-risk groups;
• the introduction of harm reduction interventions (e.g.
needle exchange schemes, methadone substitution
programmes and overdose prevention initiatives);
• increasing coverage of such schemes and improving
access among high-risk populations: marginalised
groups such as the Russian-speaking community,
Romany youth, prisoners, sex workers, migrants and
immigrants;
• reducing stigmatisation and social exclusion.
The final challenge in many of the CEECs is to ensure the
regular availability of good, up-to-date data on HIV and
other drug-related infectious diseases, especially
hepatitis C, as well as to improve the quality of mortality
data. In particular, the lack of any data from Romania on
harm reduction on the agenda and helped generate
momentum towards its recognition and acceptance as an
important element of a balanced drug policy. In other
countries, that process is only now taking place.
Types and extent of harm reduction measures
Details of responses to drug-related health damage are
given in the 2002 report on the drug situation in the
candidate CEECs (EMCDDA, 2002a) and in Chapter 3 of
this report. All CEECs have now implemented harm
reduction measures, at least to some degree. These include
(as far as data are available) information dissemination,
low-threshold drop-in centres, outreach programmes,
access to clean injecting equipment, distribution of
condoms, counselling and testing for HIV, HIV/AIDS
treatment and, in some cases, hepatitis B vaccination.
Access to services varies considerably, however, and in
some cases is quite limited. In most countries, provision and
coverage of key preventative and harm reduction measures
are very limited compared with the prevalence of problem
drug use and the scale of potential consequences over the
next few years. While needle and syringe exchange
programmes (SEPs) have been implemented in all countries,
only the Czech Republic reaches a substantial proportion
(estimated at over 50 %) of drug injectors through a
national network of SEPs and low-threshold projects,
although in some countries, such as Slovenia, a reasonable
level of coverage is achieved in some cities. As noted
earlier, coverage of methadone substitution treatment,
which can help reduce health damage, including drug-
related deaths and infectious diseases, is extremely limited
in all countries except Slovenia.
Most harm reduction responses are aimed at preventing 
drug-related infectious diseases. Relatively few focus on
preventing drug-related deaths, although some measures,
such as methadone programmes or outreach projects
providing health information and improved access to services,
may also make an important contribution in this area.
Issues and challenges
The risk of new epidemics of infectious diseases, not only
HIV infection but also HCV, among drug injectors is a
major public health challenge in the CEECs. Low HIV
prevalence in most countries, and relatively low HCV in
some, is no basis for complacency, as exemplified by recent
and sudden increases in HIV in the Baltic States and
neighbouring countries to the east. Furthermore, a wide
range of continuing high-risk behaviours and broader high-
risk contexts suggest that strengthening public health
measures to prevent the spread of HIV and hepatitis C in
drug-injecting populations and to minimise the number of
drug-related deaths is a high priority.
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the prevalence of problem drug use, injecting, HIV infection
and hepatitis C is cause for serious concern.
Drug markets
This section gives a brief summary of the evolution of illicit
drug markets in central and eastern Europe over the past
15 years and comments on some implications. More
information on drug markets and drug-related crime is
provided in Chapter 4 of the 2002 report on the drug
situation in the candidate CEECs (EMCDDA, 2002a).
Drug trafficking
The geopolitical situation in central and eastern Europe
has been a key element in drug trafficking patterns for over
20 years. Since the late 1970s, heroin from south-west Asia
has been transported along the Balkan route from Pakistan
and Afghanistan through Iran, Turkey, Bulgaria and
Yugoslavia to western Europe. In other parts of the region,
authoritarian regimes and strict controls on the movement
of goods and people limited the extent of drug trafficking
until the events of 1989 changed the situation. In the early
1990s, war in Yugoslavia disrupted the Balkan route and
led to diversification of trafficking through Bulgaria,
Romania, Hungary and, to some extent, Slovakia. While
relaxation of border controls facilitated drug trafficking
through the region, at that stage western rather than local
markets were the primary destination. However, the war did
contribute to increased heroin use in parts of Yugoslavia.
While heroin was the main drug, significant seizures of
cannabis and cocaine were also made.
Later in the 1990s, intensification of the conflict in
Kosovo increased the significance of Albanian/Kosovan
involvement in drug trafficking. This mainly affected Italy,
Greece, and also Switzerland, until, in 1999, Italy
tightened its borders to reduce refugees from Kosovo,
leading to increases in trafficking through the Czech
Republic.
The disintegration of the Soviet Union in 1989 was another
important factor that increased the diversity of trafficking
routes, one new route being the so-called Silk Route from
the central Asian States through Russia, the Ukraine, Poland
and the Baltic States. In addition to heroin, this also
increased the supply of poppy straw to the Baltic States.
Currently, a wide range of routes are used for trafficking of
heroin from south-west and central Asia, often variations of
both the Balkan and Silk Routes. In contrast to the situation
10 years ago, end-markets now include the countries of
central and eastern as well as western Europe. In addition,
trafficking routes for cocaine and cannabis pass into and
through the Baltic and Balkan regions, circumventing
controls on traditional routes through west European
countries such as Spain, the Netherlands or the United
Kingdom. Trafficking in amphetamines has also emerged,
especially from eastern or central Europe to the west, and
trafficking in ecstasy and other synthetic drugs, which
initially came from western European countries such as the
Netherlands, now occurs in both directions.
Domestic drug production
Where there is a tradition of opium poppy cultivation for
legitimate purposes such as poppy seed for culinary use (the
Baltic States, Bulgaria, Hungary and Poland), some domestic
production of opiates continues, although generally at a
lower level than in the past. This reduction partly reflects
increased availability of imported heroin but also, as in
Poland, a move towards cultivating strains of low-opium-
producing poppies. Following privatisation and diminished
regulation of the chemical and pharmaceutical industries
after 1989, uncontrolled production of psychotropic
substances, notably amphetamines, increased, for example
in Poland. Since then, production of synthetic drugs, such as
amphetamines and ecstasy, in illegal laboratories has also
been found in other countries, including the Baltic States,
Bulgaria, the Czech Republic and Hungary. Domestic
demand for Pervitin, which is produced for home
consumption in the Czech Republic, appears to be falling, as
heroin replaces the drug in the domestic market. Some
manufacture may now be intended for export. There are no
reliable estimates of domestic cannabis cultivation, although
it is reported from some countries.
Drug availability
Drug availability depends on the extent of drug
distribution and supply in any particular country and on
how the markets function in terms of who has access to
drugs and under what conditions. Different indicators
reflect different aspects of drug availability and are not
always consistent either with each other or with indicators
of the demand for drugs.
Statistics on quantities of drugs seized often combine drugs
seized in transit with those destined for domestic markets,
and in any case may not give a reliable indication of the
true scale of the supply of different drugs as a few large
seizures can seriously distort the picture. The number of
seizures made by police (as opposed to customs officials)
may sometimes give an indirect measure of availability in
a country, although this too is affected by police priorities
and activities. In most countries, the number of seizures
of cannabis is increasing, while recent trends for heroin,
amphetamines and cocaine vary, being stable or fluctuating
in some countries and increasing in others. Price data are
incomplete and rarely available on a consistent basis over
time, especially not in a comparable format that takes
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One implication is that, as in western Europe, it may be
unrealistic to expect that drug use, and especially more
damaging patterns of problem use and correlates such as
drug-related crime, can be reduced through measures to
reduce supply and availability alone. The challenge is, then,
to develop drug control policies that balance supply
reduction with adequate demand reduction responses. As
with drug use, the expansion of drug trafficking and drug
supply can be seen in the wider context of recent historical,
economic and social changes in central and eastern
Europe. Despite local variations in how drug trafficking and
distribution are organised and differences in the
characteristics of the groups involved, there are common
elements cutting across all these developments, from the
Balkans, through central Europe and the ex-Soviet States, to
the Baltic region. All arose in a context of rapid political
and economic change, with an associated breakdown in
established structures and control mechanisms. In many
cases these were replaced by free market systems that
lacked effective regulatory processes, creating crises of
legitimacy as well as opportunities to profit rapidly for
those with power or influence. Civil wars, armed conflicts,
economic impoverishment, migration and refugee crises
all further contributed to this process. It was inevitable that
these factors stimulated the growth of organised crime
and corruption and that substantial increases in trafficking
of people, sexual services, stolen cars, alcohol, tobacco
and arms, as well as drugs, have been observed over
the past 10 to 15 years.
The implication is that responses conceived from a policy
perspective focused specifically on drugs, for example
increasing border controls or improving drug detection
technology, are too narrow. Broader strategies are needed
to respond to the phenomenon of organised crime as a
whole, including the financial structures and political
associations that support it and the social and economic
conditions that often underlie it. This, in turn, raises much
broader social and economic issues, such as fostering
inclusion and development, reinforcing the stability
and legitimacy of political and social institutions or
strengthening economic regulatory mechanisms for
managing and reducing the negative consequences
of social and economic change.
At the level of drug policy in particular, a major challenge
for politicians, officials and professionals involved in law
enforcement and criminal justice is to integrate their
strategies and activities into the wider global approaches
that are only now evolving in many countries. This entails
developing cooperation at national and local levels with a
range of new partners from diverse fields such as health,
education and social welfare, including NGOs and other
account of broader inflation rates. The limited data broadly
suggest that prices are not increasing, regardless of the
number of drug seizures or quantity of drugs seized.
Measures of the perceived availability of different drugs
by potential consumers such as young people provide an
alternative indicator of availability. For example, in all
countries taking part in the ESPAD surveys in 1995 and
1999 there were significant increases over four years in the
perceived availability of cannabis, LSD and ecstasy among
16-year-old school students. Similarly, perceived availability
of inhalants increased but there were no corresponding
increases in prevalence of this type of drug use.
Responses
It is outside of the scope of this chapter to review the
development and characteristics of law enforcement
strategies and responses to drug trafficking, supply and
drug-related crime across the region. At a very general
level, it appears that during the first half of the 1990s
higher priority was often devoted to interdiction and law
enforcement. This emphasis was in part encouraged by
west European countries, which were alarmed by potential
increases in drug trafficking and organised crime across
borders that previously had been strictly controlled. Over
the course of the decade several countries moved towards
approaches that placed increased emphasis on prevention,
treatment and reducing drug-related damage.
As explained in Chapter 4 of this report, all 10 CEECs have
now adopted or are in the process of adopting new or
revised drug strategies that are oriented towards global
approaches that aim for a balance between demand and
supply reduction. This shift was influenced by several
factors, such as training and technical assistance in demand
reduction provided through programmes supported by the
Pompidou Group and the EC Phare programme and, more
recently, through preparatory work for accession, including
Phare twinning projects with EU Member States and
participation in the activities of the EMCDDA.
Issues and challenges
Despite limitations, available data, including qualitative
assessments and indicators of drug demand described
above, suggest that the supply and availability of
cannabis, ecstasy, LSD, amphetamines, heroin and,
to a lesser extent, cocaine increased over the last decade
in central and eastern Europe, as did their use. It was
also suggested earlier that, although changes in drug
availability influenced patterns of use, increases in drug
use and in more risky, problem, use were primarily
driven by underlying social and economic processes
and by changes in youth culture, perceptions
and expectations.
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sections of civil society. A further challenge will be to
evaluate the impact and effectiveness of legislation and law
enforcement as part of the process of identifying how they
can contribute to achieving the goals of those global
strategies. Recent evaluations in Hungary and the Czech
Republic have touched on some aspects of this approach,
but much remains to be done.
Public health and social policy:
key challenges for the future
This section draws together conclusions of the analyses
presented above and summarises major challenges
for the future.
Social perceptions of drugs
How drug use and drug problems are perceived in society
plays a fundamental role in the policy arena. Social
perceptions not only help to shape the sorts of drug policies
that are constructed and accepted but are themselves
important consequences of drug policy. The historical
account provided earlier in this chapter suggests that
perceptions of drug use as a deviant, sociopathological
phenomenon were a key element underpinning the
particular forms of repressive policies that developed in
much of central and eastern Europe. Those policies, in turn,
had serious consequences in terms of maintaining
ignorance, reinforcing stigmatisation and creating mistrust
of official treatment institutions. As new drug use patterns
emerged, and as the legitimacy of broader political and
social structures came under increasing challenge, it
became even more apparent that existing policies were ill-
suited as a basis for responding, but the legacy of social
perceptions of drug use among the general population,
politicians and professionals alike presented significant
barriers to change.
Over the course of the 1990s, several elements in this
interconnected construction of policies, perceptions and the
actual drug situation began to shift, more so in some
countries than in others, and drug policies and perceptions
of drugs began to change. Some possible reasons for this
were noted earlier, such as wider social and economic
changes, greater exposure to alternative perspectives on
drugs and drug policy or improved information on drug use
and its consequences. However, in many countries
uncertainty and ambivalence are predominant
characteristics of social attitudes and perceptions towards
drugs and drug users among both the public and
professionals. This makes it more difficult to develop and
implement coherent and effective strategies that enjoy
public, political and professional support.
Thus, a major challenge is to build a broad consensus that
has public as well as political and professional support for
long-term policies and strategies based on evidence and
experience of what is likely to be effective.
Drug demand reduction
Major challenges for demand reduction responses were
identified earlier and can be summarised as follows.
Prevention and early intervention
Build on initiatives giving priority to local, broadly
conceived community-based initiatives adapted to local
circumstances rather than rely exclusively on national
school-based programmes or media campaigns. In
particular:
• identify vulnerable groups and specific situations
associated with riskier patterns of drug (and alcohol)
use and develop more targeted, contextualised
responses;
• invest in capacity building, especially awareness raising
and training of teachers, youth workers, social workers,
general practitioners, psychiatrists, local authority
officials, health workers and police.
Treatment
Develop more comprehensive treatment systems, based on
longer-term strategic planning, that offer a range of
services to meet the substantial level of demand that will
arise over the next decade. In particular:
• develop a comprehensive range of treatment options
and strengthen the role of civil society and NGOs;
• expand substantially the provision of treatment,
including, where appropriate, substitution programmes;
• develop treatment responses in the context of wider
actions on social exclusion and improving access to
services.
Harm reduction
Develop a comprehensive strategy and muster the political
will and resources to implement it on a scale sufficient to
meet the serious and worsening level of drug-related health
and social damage associated with problem drug use,
especially drug injecting. In particular:
• defuse anxiety about harm reduction through information
provision, awareness raising and informed discussion
among policy-makers, professionals and the public;
• expand substantially the range and coverage of
appropriate harm reduction interventions to prevent the
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• How to coordinate policies and responses across
different domains (health, education, justice,
international relations, research, etc.). Chapter 4
describes the progress that has been made in this
respect.
• How to involve not only various government
departments but also the wider community (civic society,
media, NGOs, local authorities, etc.). While this poses
challenges everywhere, it is of particular relevance
in the recent historical context of central and eastern
Europe.
Proportional and cost-effective policies
It should be clear from the analysis presented previously
that many individual and contextual factors influence
patterns of drug use and their consequences, and that there
are important differences in terms of the resultant costs for
individuals and society. A balanced and comprehensive
approach to the drugs issue does not mean that all aspects
should be given equal weight and allocated equal
resources. Rather, as resources are inevitably limited, the
policies adopted should be proportional, i.e. the
importance accorded to them should be correlated with
their perceived priority, and they should be cost-effective
in terms of targeting interventions that give best value
for money. Thus, a fundamental challenge is to develop
policies that:
• are based on analysis of differential vulnerability, risks
and consequences;
• specify priorities, objectives, target populations and
settings;
• propose interventions based on evidence of effectiveness
and cost.
Information, monitoring, evaluation and research
Reliable and relevant information is essential for
underpinning policies aiming to be proportional and 
cost-effective. At European level, this is the rationale
for the EMCDDA and its network of national focal points.
However, the national focal points, along with other
centres at regional and local level, can also play a key role
in collecting and synthesising information to inform national
policy development. It is therefore essential that national
focal points in central and eastern Europe are given
adequate and long-term support. Key points include
the following.
• Improved data gathering and analysis is a necessary
first step in determining the scale and characteristics
spread of HIV and HCV and to minimise drug-related
deaths;
• improve access to services for high-risk populations,
including minorities and prisoners, and place a high
priority on measures to counteract stigmatisation
and exclusion.
Local needs assessments and monitoring local responses
Local diversity is a common theme cutting across all the
domains of drug demand reduction. This means that
national surveys and indicators should be complemented at
regional and municipal level by local needs assessments to
identify priorities for action and by monitoring local trends
and interventions to keep track of the local situation and
improve the match between responses and problematic
developments in drug use. These need not be large-scale,
expensive research programmes but can be based on
intelligent exploitation of existing indicators and data from
local agencies. Information dissemination and rapid
feedback to local services and professionals are essential
if local monitoring is to be useful in guiding policies.
Drug policy issues
Law enforcement and interdiction
Although drug supply, availability and drug-related crime
are not covered in detail, it is suggested above that the
countries of central and eastern Europe are now an integral
part of wider European markets in terms of both
international trafficking and domestic supply and demand.
A major challenge is to accept that the role of law
enforcement should now be viewed not as the relatively 
self-contained task of disrupting drug trafficking through
the region, but rather as part of a global approach based
on the implicit assumption that supply reduction activities
are unlikely to be effective alone if they are not matched
with investment in demand reduction work.
A balanced and comprehensive approach
The concept of a balanced approach to drug policy has
become more prominent over the past 10 to 15 years and is
now gaining wider acceptance in central and eastern
Europe, with more attention being paid to demand reduction
(see Chapter 4). The challenge now is to increase acceptance
of this approach and broaden implementation of public
health policies across the domains of information, prevention,
early intervention, harm reduction and treatment.
The notion of a balanced approach implies one that is
comprehensive in terms of covering the range of significant
actors and parties involved. This raises two specific
challenges.
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of the drug phenomenon and in describing current
responses and assessing if they are sufficient
and appropriate.
• Assessing the situation is not enough. Monitoring is
needed to determine how both the drug situation and
the responses are changing, and evaluation is needed
to understand what is effective.
• Interpretation is the key to understanding what is
happening and why, and to anticipating trends and
identifying what is needed.
Assessing the drug situation and monitoring trends and
responses at national or subnational level implies
implementation of key indicators and regular collection of
other core data, as well as discussion with key experts to
interpret what these data imply for national or local policies
and strategies. It also implies paying attention to standards
and quality assurance. This, in turn, implies dedicating a
(modest) proportion of national and local budgets to data
collection and analysis.
Identification of explanatory factors and causal
mechanisms, as well as scientific evaluation of
interventions, often requires more substantial research,
qualitative as well as quantitative, and is best carried out
by specialised centres with accumulated expertise in the
area. This requires a specific budget to be allocated to the
development of research programmes at national and,
where relevant, regional level.
Wider social and ethical issues
Drug use and drug-related problems are closely
interlinked with a variety of wider social issues across
different domains and raise challenges for policy-makers
extending far beyond the field of drugs. The account of
the evolution of the drug phenomenon given in this
chapter has stressed the central role of a range of social
and economic factors. This implies that drug policies must
be linked to policies on wider issues that influence drug
use and its associated risks. These might include regional
and local economic policies, youth employment and
training schemes, housing and community regeneration
programmes, public safety and crime prevention
programmes, strategies on organised crime or equal
opportunities and social inclusion policies.
The final and perhaps most critical challenge is to build
drug policies based on respect for human rights and all that
that implies in terms of promoting equal access to services,
respecting medical ethics such as patient privacy and
confidentiality, reducing stigma and, more broadly,
encouraging social inclusion and democratic participation.
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(4) Lifetime prevalence is a cumulative indicator of the total number of people who have ever tried drugs, including many in the distant past; by definition,
such use cannot be reversed (EMCDDA and Hartnoll, 2002e).
(5) Tobacco and alcohol; only the latter will be discussed in this chapter.
Main findings
The findings summarised in this chapter constitute only a
part of what we know about the use of illicit drugs and
alcohol among young people in the CEECs. It should
be emphasised that the available information comes
predominantly from students attending high schools; in
the CEECs there has been no research into indicators of
alcohol and illicit drug use in the most vulnerable groups
of young people: those not attending schools and/or
members of marginalised groups. This is the main
weakness of the data presented.
Lifetime prevalence (4) of the use of both licit (5) and illicit
drugs is the most commonly reported indicator (even if not
necessarily the most informative either from the public
health perspective or from the perspective of social risk). 
The two ESPAD studies for which results are so far available
(Hibbell et al., 1997; 2000) show that lifetime prevalence
of use of both alcohol and ‘any illicit drug’ increased
markedly in the CEECs between 1995 and 1999.
These findings have been confirmed by numerous local and
national studies performed in nearly all of the CEECs as
reported by their national focal points.
However, most 16-year-olds in the CEECs have never used
illicit drugs and, among those who have, the vast majority
have used only cannabis. On average, lifetime prevalence
of illicit drug use by 16-year-olds in the CEECs is 19 %,
ranging from 12 % in Romania to 35 % in the Czech
Republic. On average, the lifetime prevalence of cannabis
use by 16-year-olds in the CEECs is 16 %, ranging from
1 % of the surveyed population in Romania (although 8 %
have tried smoking heroin at least once) to 34 % in the
Czech Republic. In contrast, in almost all of the CEECs,
more than 90 % of 16-year-olds have tried alcohol at least
once, and nearly two thirds admit to having been drunk at
least once in their life.
As regards attitudes to drug use among 16-year-olds in
1999, in all CEECs the percentage of young people who
disapproved of getting drunk once a week was very similar
to the number who disapproved of experimenting with
cannabis, although the actual rates of disapproval did vary
between countries. This finding, already apparent from the
limited data presented in the 1995 ESPAD study, is even
clearer in the 1999 data set (Figure 4). This situation may
reflect the increasing ‘normalisation’ of experimenting with
cannabis (and of getting drunk) among young people.
In 1999, disapproval of ‘getting drunk’ was greater than or
equal to disapproval of ‘cannabis experimentation’ in the
Czech Republic, Latvia, Slovakia and Slovenia. Disapproval
of cannabis experimentation was significantly higher than
disapproval of alcohol use in Bulgaria, Hungary, Romania
and Lithuania. In Estonia, the difference between the two
ratings was statistically insignificant. Both disapproval
ratings decreased in all countries for which data from both
1995 and 1999 are available, but especially those for
cannabis experimentation. Given that alcohol use is
culturally embedded in the CEECs, this could suggest that
experimental and recreational use of cannabis will increase
in the future among young people in these countries.
In any case, at least as far as attitudes are concerned,
we can clearly distinguish a trend of rapidly increasing social
acceptance of cannabis experimentation among young people
in the CEECs. This trend is very similar to that experienced
by the current Member States only a few years ago.
In two CEECs, disapproval of psychotropic substance use,
and particularly cannabis use, is much lower than elsewhere.
In the Czech Republic and Slovenia, the percentage of 16-
year-olds who disapprove of experimenting with cannabis or
getting drunk once a week is less than 50 % of the surveyed
population (Figure 4B). These findings have been confirmed
in other national as well as local studies and they fit well with
the fact that lifetime prevalence of cannabis use is also
highest in these two countries. Lifetime prevalence of any
alcohol use is also higher than the CEEC average in the
Czech Republic (98 %) and Slovenia (91 %), with the Czech
Republic showing the highest level of all the CEECs. Thus, the
Czech Republic is one of the three European countries which,
according to ESPAD, have the highest lifetime prevalence of
Chapter 2
Drug and alcohol use among young people
This chapter looks in detail at what is known about the changing picture of drug and alcohol
use among the young and complements a similar focus piece in the accompanying report 
on the state of the drugs problem in the European Union and Norway.
35
Figure 4B: 1999
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decrease in negative attitudes to their use described above,
the effectiveness of primary prevention measures could be
questioned. In practice, very little is known about the
quality and effectiveness of prevention programmes in the
CEECs. Moreover, there is a great deal of confusion about
terminology: there is no general consensus as to whether
the term ‘drug (primary) prevention’ describes only
activities that specifically target drug use or if it also
encompasses initiatives that promote a ‘healthy lifestyle’
in general, in other words, support for activities that are
alternatives to drug use.
alcohol use (the other two are Denmark and Greece),
whereas the figure for Slovenia is slightly above the ESPAD
average of 89 %.
All CEECs have in place a large number and wide range
of primary prevention initiatives, including the provision
of sport and music facilities, mass media campaigns,
distribution of educational materials and school and
community programmes. However, considering the recent
increase in the prevalence of lifetime use of psychotropic
substances among young people and the corresponding
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Figure 4: Disapproval of weekly drunkenness and cannabis use among 16-year-olds.
Figure 4A: 1995
Source: ESPAD school survey project (1995 and 1999).
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(6) Unrecorded alcohol consumption (i.e. consumption of illicit and/or home-made alcoholic beverages) values are included only when available.
(7) In the case of 16-year-olds, Csemy defined ‘heavy drinking’ as drinking alcoholic beverages containing in total at least 100 mililitres of pure alcohol
(ethanol) on three or more occasions in one month.
(8) From 12 % in 1995 to 23 % in 1999.
(9) From 13 % in 1995 to 21 % in 1999.
(10) From 14 % in 1995 to 23 % in 1999.
(11) From 32 % in 1995 to 41 % in 1999.
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Primary prevention is by far the most popular measure in
the drug field in the CEECs (see, for example, Kenis et al.,
2001); however, evaluations of primary prevention
initiatives are usually limited to a listing of activities,
persons/children involved in the activities, and in some
cases also the costs of the initiative. This further supports
the need for promotion of an evaluation culture, but it also
highlights the opportunities for the CEECs to benefit from
progress made by EU Member States in this field during the
last decade.
Comparative analysis of available data
Prevalence, trends and patterns of use
According to ESPAD studies, lifetime prevalence of use of
alcohol and illicit drugs increased in all CEECs between
1995 and 1999. Although the increase in lifetime
prevalence of alcohol use was relatively small (but it should
be borne in mind that levels were already high, around
90 %, in all CEECs in 1995), the lifetime prevalence of illicit
drugs increased significantly in all CEECs without
exception. Among the countries for which results from both
1995 and 1999 ESPAD studies are available, the greatest
increases occurred in Lithuania (eightfold — from 2 to
16 %), Latvia (fourfold — from 5 to 21 %) and Hungary
(threefold — from 4 to 13 %).
More important from the public health perspective is the
increase in high-risk patterns of use of both alcohol and
illicit drugs.
Alcohol
According to the WHO (1999), ‘[…] with the exception of
the far eastern part of the region (e.g. the Islam-influenced
republics of the former Soviet Union), countries in the
European region have the highest adult prevalence of
drinking in the world’. Indeed, some of the total values for
recorded and unrecorded (6) alcohol consumption per
person in the CEECs are striking (Table 1).
Traditionally, alcohol is widely accepted as a part of social
activities among adults in the CEECs, and, understandably,
the attitudes of young people reflect this.
According to Csémy et al. (2000), the average calculated
consumption of 16-year-old heavy drinkers (7) in the Czech
Republic is 9.8 litres of pure alcohol (ethanol) per year —
a level very similar to the average annual per capita
consumption (10.2 litres).
An indicator that reflects the ability of minors to obtain large
quantities of alcohol, ‘being drunk up to 13 years of age’, is
also examined in the ESPAD studies. The value of this
indicator in 1999 was highest in Romania (22 %), followed
by Estonia and Slovenia. Starting to drink at a young age is
generally considered to be an important indicator of future
substance use, school failure and delinquent behaviour (see,
for example, Ellickson et al., 2003).
The number of 16-year-olds who can be described as
‘experienced drinkers’ (defined as having consumed alcohol
on 40 or more occasions in a lifetime) increased
substantially in all countries except Hungary. The highest
relative increases occurred in Lithuania (8), Estonia (9) and
Slovenia (10), while the highest percentage of experienced
drinkers was found in the Czech Republic (11) (Figure 5).
An emerging trend that is even more serious from the
public health perspective is a clear increase in high-risk
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Table 1: Alcohol consumption per person 
in the CEECs (litres of pure alcohol per year)
Country Recorded Estimated unrecorded 
consumption consumption 
(where available)
Bulgaria 6.8 n.a.
Czech Republic 10.2 n.a.
Estonia 2.4 6.0
Hungary 9.4 10.1
Latvia 7.1 14.2
Lithuania 12.0 6.5
Poland 6.2 1.5
Romania 9.5 n.a.
Slovenia 11.7 7.5
Slovakia 8.3 n.a.
Source: ‘World drink trends 1999’ and ‘Health for all’ database, WHO Regional
Office for Europe; quoted in Rehn et al. (2001).
(12) The exceptions are the WHO coordinated studies ‘Health behaviour in school-aged children’ (see, for example, Settertobulte et al., 2001).
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drugs). However, many of these studies do not meet the
standards for sampling procedures or for the use of
appropriate methods to address the questions to be
answered. Further efforts are required to implement
European standards in order to achieve better
comparability at both national and international level.
Increases in the indicator of lifetime prevalence of use (of
any illicit drug) found in the ESPAD studies have already
been described and thoroughly analysed in the two
previous EMCDDA reports dealing with the drug situation in
the CEECs (EMCDDA, 2001; 2002a). Where new studies
are available at either a national or regional level, they
confirm that the trend in lifetime prevalence of cannabis use
has continued upward since 1999. In addition, in some
countries, e.g. Bulgaria and the Czech Republic (see
Mravcˇ ík and Zábransky´, 2001), there has been a decrease
in the use of ‘hard drugs’, i.e. opiates/heroin,
amphetamines and cocaine, and sometimes also a decrease
in solvents abuse.
A study of drug use among 15- to 16-year-olds carried
out in the Bulgarian capital, Sofia, in 2001 found the
lifetime prevalence of any illicit drug use in this group to
be 27.2 % (compared with 14 % according to ESPAD
1999). Again, cannabis was the most commonly used
drug (26.9 % admitted to having tried cannabis
compared with 11 % of this age group in Bulgaria as a
whole in 1999). In addition, lifetime ecstasy use was
patterns of alcohol use, so-called ‘binge drinking’. For some
young people (‘heavy drinkers’) alcohol consumption is no
longer just a social activity, but instead alcohol is valued
also for its relaxant effect, being used to forget worries,
calm down and ‘chill out’ — a development seen also
in the United Kingdom and elsewhere (see, for example,
Egginton et al., 2002). In other words, alcohol is
appreciated for its ‘mind-altering’, psychotropic effects.
The pattern of binge drinking associated with the highest
risks is frequent drinking of large amounts, a pattern that is
risky not only from the medical point of view but also
because of the risk of violence associated with it. Alcohol
may be more likely than other drugs to be a contributory
factor in acts of violence (Secretary of Health and Human
Services, 2000). Among the CEECs, the greatest increase in
the indicator ‘consumption of five or more drinks on six or
more occasions in the last 30 days’ was found in Poland
(up from 4 % in 1995 to 19 % in 1999) (Figure 6). This is
an important indicator of very frequent high-risk ‘binge’
drinking. The highest value of this indicator in 1999 was
also found in Poland, followed by Slovenia (14 %), which
also experienced a sharp increase.
Illicit drugs
Overview
In the CEECs, surveys on illicit drugs are more common
than those targeting alcohol (12) (or both licit and illicit
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Figure 5: Percentage of 16-year-olds who have consumed alcohol on 40 or more occasions in their lifetime
Source: ESPAD school survey projects (1995 and 1999).
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(13) Also covered by EMCDDA’s Drugs in focus 6 (EMCDDA, 2002f).
(14) Used at least once during one’s lifetime.
(15) The study, ‘Ecstasy and young people’, was led by John Marsden and conducted within the framework of the WHO global research programme on
amphetamine-type stimulants (ATS) to examine ecstasy use among young people aged 16–25. The total sample size was 100.
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significantly higher than in Bulgaria as a whole in 1999
— 4 % compared with 1 %. Nevertheless, there was no
increase in lifetime prevalence of use of drugs associated
with the highest risk patterns of use; cocaine use
remained stable at 2 % and a decrease in the lifetime
prevalence of heroin use among schoolchildren in Sofia
was found compared with national ESPAD 1999 results.
In Lithuania, a new ESPAD-based study was carried out in
vocational schools (schools that train students for particular
careers) in the capital, Vilnius, in 2001, with the results
showing a substantial increase when compared with the
1999 national data (Table 2).
Drugs use, dance and young people
Awareness of the importance of the phenomenon of
recreational drug use is increasing in the CEECs — a
chapter was devoted to this topic in last year’s annual
report on the drug situation in the CEECs (EMCDDA,
2002a) (13). The new information that is available suggests
that experimental and recreational use of ‘dance drugs’,
especially ecstasy, among young people is continuing to
increase, especially among party-goers. In addition,
according to research conducted since 1999, the popularity
of cannabis is not decreasing — a trend that remains to be
confirmed or refuted by the 2003 ESPAD study.
The highest lifetime prevalence (14) of ecstasy use among
16-year-olds in the CEECs is found in Latvia (6 %), followed
by Lithuania, the Czech Republic and Slovenia (4 % in each
case), and use among party-goers in the CEECs differs little
from that elsewhere in the EU. A study conducted in Prague
and six capital cities in the EU in 1999–2000 (Tossmann et
al., 2001) as well as a number of other recent studies of
the recreational drug scene, conducted in various settings
and employing both quantitative and qualitative
methodologies, have produced similar results (see, for
example, Kubu˚ et al., 2000; Demetrovics, 2001;
Allaste and Lagerspetz, 2002).
In Hungary, data from two studies were compared in all
age groups, lifetime prevalence was higher (by a factor
of 1.5–2) among a population surveyed in places of
entertainment in Budapest (Demetrovics, 2001) than in a
secondary school student population (ESPAD 1999).
However, when those born between 1981 and 1984 were
excluded from the analysis, lifetime prevalence among
party-goers was found to be 76.3 %, three times that found
in the population as a whole (25.3 %).
In 2001, the WHO conducted a study of ecstasy users in
Estonia, mostly students and schoolchildren living with their
parents (15). According to the preliminary results of the
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Figure 6: Percentage of 16-year-olds reporting having consumed five or more drinks on six or more occasions during the last 30 days
Source: ESPAD school survey projects (1995 and 1999).
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Table 2: Lifetime prevalence of illicit drug use in Lithuania, 1999, and Vilnius, 2001 (%)
Source: Lithuanian annual report 2002 and ESPAD school surveys project. Both studies used ESPAD methodology.
Narcotic/psychotropic substance Vilnius vocational schools ESPAD 1999
Overall Boys Girls Overall Boys Girls
Any 44.1 48.6 38.2 15.5 21.0 9.6
Marijuana/hashish 32.2 41.5 20.1 11.9 17.4 6.1
Amphetamine 11.5 13.9 8.3 1.5 1.9 1.0
LSD 6.1 8.4 3.2 1.4 2.9 0.7
Ecstasy 4.5 5.5 3.2 4.4 6.4 2.3
Cocaine 3.0 4.0 1.7 1.1 1.3 0.8
Crack 0.6 1.1 — 0.3 0.5 0.1
Heroin by smoking 10.6 13.2 6.6 4.1 4.9 3.3
Heroin consumed by other methods 2.9 3.8 1.7 0.7 1.0 0.3
Injection 2.5 3.5 1.1 0.5 0.6 0.4
Alcohol together with pills 9.4 10.4 8.0 6.5 7.2 5.6
Alcohol together with marihuana 12.9 16.3 8.3 4.6 7.2 1.8
‘Magic mushrooms’ 0.7 1.3 — 0.3 0.5 0.1
Anabolic steroids 3.2 5.1 0.9 0.8 1.4 0.2
No recent research into the harmful effects of alcohol use in
young people was described in the national reports of the
CEECs to the EMCDDA.
Regarding alcohol-related mortality, among young people
aged 12–18, only two deaths due to alcohol overdose were
reported from the CEECs, both in Estonia. However,
available data show that a number of deaths occurred in
the presence of alcohol — usually attributable to
consumption of psychoactive medicines (such as
benzodiazepines). In general, data regarding alcohol-
related deaths in the CEECs are almost non-existent.
Recently, interest has been aroused in the relationship
between early onset of alcohol (ab)use and abuse of
cannabis and more harmful drugs. Csemy and Nesˇpor
(2002a,b) analysed the ESPAD data, and found a
correlation between (ab)use of licit and illicit substances.
This has led to some discussion about primary prevention
principles and about the relevance for prevention of the
legal status of different substances (see also Miovsky´,
2003). In a study in Slovakia that analysed national ESPAD
data (Nociar and Miller, 2002), it was found that students
who rapidly developed alcohol tolerance were more likely
than others to have used illicit drugs. This finding was true
study, young people start to use ecstasy at an early age,
mostly at the weekends. During the three-month period
before the study, approximately one sixth of the sample
surveyed had used ecstasy once a week and about one
third had used it two or three times a month. The results of
the study also revealed that young people who use ecstasy
are likely to be polydrug users, consuming various drug
combinations including some of the following substances:
alcohol, cannabis, amphetamine, gamma-hydroxybutyrate
(GHB), cocaine and ketamine (quoted in Talu and Hammer-
Pratka, 2002).
Health and social consequences
Alcohol
Generally, there is agreement among CEEC experts that
since the fall of the communist regimes, and the consequent
removal of taboos surrounding public discussion of drug
use, the emergence of new illicit drugs has drawn the
attention of the public (and to some extent also scientists)
away from alcohol-related issues. This development has
been accompanied by increased underestimating of the
association between drug and alcohol use.
(16) As is the case in all current Member States except Austria and Spain (Rehn et al., 2001).
(17) These are all the public places where alcohol can be sold. Other possible answers to the question of where alcohol is consumed are ‘at someone else’s
home,’ ‘street, park, beach’, ‘other places’ and ‘never been drinking’.
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even after taking into account levels of alcohol
consumption.
Illicit drugs
Problem drug use
School surveys usually reveal little about high-risk patterns
of illicit or problem drug use because the prevalence of this
behaviour is very low in this environment, i.e. below the
statistical sensitivity of the surveys. The only indicator that
can be used to illustrate higher-risk patterns of drug use is
‘any drug by injection’. In both the 1995 and 1999 ESPAD
surveys, levels of this indicator were between 0 and 1 % in
all the CEECs, with only insignificant changes either way
over the four-year period.
Solvent abuse
Very little is known about the nature and scale of recent
solvent abuse by young people in the CEECs, or about the
resulting harmful effects. One reason for this is the status of
solvents as licit substances and another is the fact that
solvents are predominantly abused by the very young
and/or marginalised populations who are not reached by
routine monitoring systems or research. Solvent abuse is
clearly an area where more and better information is
essential, especially because, where data about fatal
overdoses are available (e.g. in the Czech Republic),
solvents rank highly among the causes of death.
Ecstasy and amphetamine-type stimulants (ATS)
An important finding of the Estonian research in the
recreational drug use setting (quoted in Talu and Hammer-
Pratka, 2002) was that half of the respondents in the
sample group fulfilled the criteria of dependency.
Furthermore, their access to information, counselling and
treatment was very limited. The results of the study also
found that these young people were exposed to a risk of
harm resulting from their (poly)drug use. The high
dependence rate (assessed according to DSM-IV criteria)
suggests that there is an urgent need to establish a system
of services for users of synthetic drugs.
In 2001, one ecstasy-related death was reported from the
Czech Republic. A 27-year-old man died of an overdose
after swallowing a PMA (para-methoxyamphetamine) pill
that he bought as ‘ecstasy’ in Germany. In Slovenia, two
ecstasy-related deaths were reported in 2001: one person
died from brain oedema (a possible MDMA-induced side-
effect) and the other died of heat stroke. There were more
non-fatal emergency cases of brain oedema connected with
MDMA use in Slovenia in 2001, but they were successfully
treated in hospital.
Slovenian research on ATS concluded that the use of
synthetic (and other drugs) in Slovenia by young people is
risky owing to the frequency and chaotic nature of use.
Young party-goers often mix different drugs (37.4 % of the
sample) or combine drugs with alcohol (21.0 % of the
sample). Almost half of the research sample (42.8 %)
reported having consumed a mixture of ecstasy and
amphetamines.
Demand and harm reduction responses
Alcohol
Legal control of alcohol
In only three CEECs — the Czech Republic, Slovakia and
Slovenia — are there no licensing laws related to alcohol
(Rehn et al., 2001) and all outlets have the right to sell and
serve alcohol. This probably accounts for the high degree
of acceptance of alcohol use in these three countries. In all
other CEECs, a licence is required (16).
In all CEECs, there are legal restrictions on the sale of
alcohol to people under 18, with variations in the severity
of sanctions. Little information is available regarding the
extent to which such laws are enforced.
An interesting study of 1999 ESPAD data analysed the
extent of enforcement of under-age drinking laws and
public (dis)approval of drinking among 16-year-olds.
The total number of respondents who answered ‘bar, pub’,
‘disco’ or ‘restaurant’ (17) in reply to the indicator ‘drinking
places of the last drinking day’ was very similar to the
lifetime prevalence of alcohol consumption, suggesting that
most alcohol consumption by under-age drinkers takes
place in public places. Enforcement of alcohol laws seems
to be weakest by far in the Czech Republic, which also
shows the most lenient public attitudes to under-age
drinking. Again, Slovenia is the second country in this
regard (Figure 7).
Restrictions on alcohol advertising are also an important
factor in preventing early onset of drinking as well as its
acceptance. In stable and saturated markets, the main role
of advertisements is to ensure that old consumers are
replaced by new ones and that educational messages do
not diminish alcohol consumption. Alcohol advertising
presents alcohol consumption as a safe and problem-free
practice, playing down the potential health risks and
negative consequences. Through its messages, alcohol
advertising maintains the social desirability of drinking,
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(18) The programme should receive final approval and be introduced during 2003. 
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in all targeted groups (parents, teachers, pupils) and
the programme will be rolled out throughout Slovenia
in 2003/04.
Slovenia also provides an example of an attempt to
introduce an innovative systematic approach to school-
based health prevention, based on good practices found
throughout Europe and identified by international
organisations and experts. The initiative (18) takes a
‘holistic approach’ to psychotropic substances and covers
nine main areas (see online box 1).
ignores the adverse effects of alcohol use on individual and
public health and challenges prevention objectives. These
indirect effects alone are sufficient to justify the need to
control the volume and content of alcohol advertising (Rehn
et al., 2001). Restrictions on alcohol advertising in the
CEECs are shown in Table 3.
Prevention of alcohol use
No systematic information is available from the CEECs
regarding initiatives targeted at young people to prevent
tobacco and alcohol use. A rare example comes from
Hungary and takes the form of kindergarten programmes
that are linked to the developmental psychological needs of
the relevant age group and formulate drug prevention
targets (‘Heart — Treasure chest’, ‘Adventures in the land of
fragrances’, etc.). Such programmes highlight the dangers
of legitimate drugs (mainly smoking) in the context of health
promotion, and they mostly use communication of
knowledge as the main tool. As a positive feature, they
require children’s active involvement and they have proved
to be effective. Kindergarten programmes are also reported
from Slovenia.
In Slovenia, a school-based primary prevention programme
targeting alcohol use in youth, called ‘Alcohol?
Adults may have the influence’, is being piloted in the
capital, Ljubljana, and two other regions of the country.
The methodology is based on the results of pre-testing
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Figure 7: Drinking in commercial enterprises among 15- and 16-year-olds
Source: ESPAD school survey project (1999).
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In countries that are members of the Organisation for
Economic Cooperation and Development (OECD), and thus
in which advertising of spirits is banned, alcohol
consumption is approximately 16 % lower than in countries
where no such bans are in place. In countries where
advertising of beer and wine is also banned, alcohol
consumption is about 11 % lower than in countries where
only spirits advertising is banned. Fatalities in motor vehicle
accidents are about 10 % lower in countries in which spirits
advertising is banned and about 23 % lower in countries
where beer and wine advertising is also banned. It has been
shown that a five-minute increase in exposure to alcohol
advertising increases alcohol consumption by young people
by 5 g a day (Rehn et al., 2001).
(19) See also the Hungarian 2001 evaluation of school prevention programmes described in EMCDDA and Olszewski et al. (2002: 13).
(20) Pupils from the ethnic minorities and other marginalised groups are over-represented in such schools.
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Illicit drugs
Drug prevention programmes focused (exclusively) on illicit
substances are far more widespread in the CEECs.
All available national reports prepared by Reitox national
focal points (see http://candidates.emcdda.eu.int) cite a full
array of prevention initiatives, including school-based
programmes, peer programmes, telephone help lines and,
more recently, community-based programmes.
Nevertheless, only in a very small number of cases does
the information provided extend further than quantification
of the number of people who have been exposed to the
programme(s) with no scientific evidence of any benefit.
Despite this, a few examples indicating a nascent culture of
evaluation of preventative activities can be listed (19).
The major methodological problem that needs to be
mentioned here is that, in all CEECs, school surveys fail to
target the youth groups at greatest risk — the socially
marginalised or excluded. This fact obviously reduces the
reliability of such surveys. Although all of the countries
have ‘special’ (20) elementary schools for so-called
disadvantaged children, and qualitative information
suggests that abuse of illicit drugs, alcohol and solvents is
substantially higher in this group than in the population as
a whole (see, for example, Grund et al., 2000), to date no
research into this issue has been carried out in the CEECs.
In the Czech Republic, a study entitled ‘Influencing attitudes
against use of drugs and other addictive substances’ was
carried out by the Hygienic Station Teplice (Sˇevcˇík, 2001).
A sociological survey was conducted in three districts at
two time points to determine attitudes to drug use. In only
one of the districts were prevention initiatives (following
the principles of community-based prevention) implemented
during the study period. The results showed an increase
in disapproval of drug use in the district where prevention
was delivered compared with two other districts.
The outcome of this study lends support to those who
believe in the positive effects of complex community-based
prevention programmes.
Some evaluation has also been carried out regarding
the preventative role of sport activities in childhood, most
recently in Slovakia and Hungary.
Okruhlica et al. (2001) administered a simple questionnaire
survey to heroin users and, as controls, a random sample of
high-school students. They found no statistically significant
difference between the groups, in either males or females, in
terms of history of sports activities up to the age of 15.
Vingender and Sipos (2001) examined the relationship
between sports and smoking, alcohol use and drug use.
The authors divided a sample of 1 103 secondary school
students into four groups (those performing at a competitive
level; those for whom sport was a leisure pursuit; those who
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Country Spirits Table wine Beer
TV Radio Print Billboards TV Radio Print Billboards TV Radio Print Billboards
media media media
Bulgaria Restricted Restricted Restricted Restricted Restricted Restricted Restricted Restricted Restricted Restricted Restricted Restricted
Czech Republic Voluntary Voluntary Voluntary Voluntary Voluntary Voluntary Voluntary Voluntary Voluntary Voluntary Voluntary Voluntary
code code code code code code code code code code code code
Estonia Restricted Restricted Restricted Restricted Restricted Restricted Restricted Restricted Restricted Restricted Restricted Restricted
Latvia Banned Banned Restricted Restricted Restricted Restricted Restricted Restricted Restricted Restricted Restricted Restricted
Lithuania Restricted Restricted ? ? Restricted Restricted ? ? Restricted Restricted ? ?
Hungary None None None None None None None None none none none none
Poland Banned Banned Banned Banned Banned Banned Banned Banned Banned Banned Banned Banned
Romania Restricted Restricted Restricted Restricted Restricted Restricted Restricted Restricted Restricted Restricted Restricted Restricted
Slovenia Banned Banned Banned Banned Banned Banned Banned Banned Banned Banned Banned Banned
Slovakia Banned Banned Restricted Restricted Banned Banned Restricted Restricted Voluntary Voluntary Voluntary Voluntary
code code code code
Source: Based on Rehn et al. (2001) as updated by national focal points.
Table 3: Restrictions on alcohol advertising in the CEECs, 2002
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with realistic information about the dangers of drug
overdose and the potential harmful effects of so-called
recreational drugs. The initiative attracted criticism and was
not repeated in 2001. However, the other CEECs continue
to develop specialised services according to local needs.
In Hungary, a programme for safe entertainment venues
was developed and launched, with the primary aims of
reducing drug use in music and dance clubs and discos
and of managing health risks resulting from drug use.
Subsequently, the Hungarian Association for Safe
Entertainment Venues was formed.
Of all the CEECs, only the Czech Republic conducts harm
reduction activities in this setting. This involves on-the-spot
(qualitative) pill testing combined with quantitative testing
of pill samples and publication of results on the Internet.
Conclusions
From the rather patchy information available regarding
alcohol and illicit drug use among young people and
relevant responses in CEECs, we can draw the following
conclusions:
• Although lifetime prevalence of cannabis (and probably
ecstasy) use is still increasing in the countries for which
new data are available, the situation regarding use of
higher-risk drugs such as heroin and amphetamines
among 16-year-olds is much less clear.
• Alcohol use in young people is widespread in the
CEECs, and the prevalence of high-risk ‘binge drinking’
is increasing.
• Neither licit nor illicit drug use among marginalised
groups (outside school or in special schools) receives
sufficient attention in the CEECs.
• The importance of the phenomenon of recreational
drug use for interventions and drug policy as a whole
is increasingly recognised in the CEECs, although
a clear consensus on appropriate intervention strategies
in this area does not exist.
• In some countries, the link between illicit and licit drugs
use is attracting increasing attention. Among 16-year-
olds in most of the CEECs, disapproval of weekly
drunkenness and cannabis experimentation is more or
less equal.
• Evaluation of prevention activities in the CEECs remains
patchy.
• Laws intended to protect children and young people
from alcohol use are often poorly enforced.
used to do sports but had stopped by the time of the study;
and students doing no sports), and compared the intensity
of use of various substances in the different groups. They
found that taking part in sports activities does not protect
against substance use, but that giving up sport is
associated with drug use and could be predictive of
future drug use (Vingender and Sipos, 2001). However,
the correlation is not strong, and step-by-step regression
analysis was unable to add any sports-related variables
to the model of drug use.
Recreational users whose drug consumption occurs
principally in places of entertainment constitute another
important target for effective prevention. In the recreational
setting, the use of both licit and illicit drugs is widely
accepted, although ‘addiction’ and/or problem drug use
remains frowned upon (see, for example, Allaste and
Lagerspetz, 2002).
Neither general ‘education’ campaigns nor measures
aimed specifically at problem drug users have had an
impact on drug users in the techno and dance scene.
In addition, it is difficult to carry out a focused campaign
because of the social diversity of such users. One possible
setting for a targeted campaign could be places and social
events where young people who are potential users of
‘new synthetic drugs’ meet, i.e. raves, parties, dance
events, dance clubs, etc.
The Czech Republic, Estonia, Hungary, Latvia and Slovenia
report targeted prevention efforts in this environment. In
Estonia in 2000, efforts were made to target recreational
users, especially female party-goers, and to provide them
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Programmes aimed at preventing illicit drug use or problem
drug use should only be part of a wider curriculum designed
to prevent problems associated with the use of all
psychoactive substances, including alcohol and tobacco.
According to recent estimates from the WHO, in Europe and
other developed countries, alcohol and tobacco account for
a much larger proportion of disease and disability than
illicit drugs: more than 21 % compared with less than 2 %
respectively (Ezzati et al., 2002).
Prevention programmes aimed at young people need to take
into account the strong overlaps between smoking, drinking
and illicit drug use in youth culture, and particularly
between intoxication from alcohol and from drugs. In view
of these links, there is a risk that a narrowly based illicit
drug prevention approach will lack credibility among young
people (Room, 2003).


Introduction
Drug-related infectious diseases among injecting drug users
(IDUs) are an important challenge to public health. Such
diseases include HIV, hepatitis C virus (HCV) and hepatitis B
virus (HBV) infection as well as some other serious diseases.
As HIV, and to a lesser extent HBV and HCV, can be
transmitted by sexual intercourse, the potential for spread
via unprotected intercourse to the sexual partners of IDUs
as well to the sexually active general population that does
not inject illicit drugs is high. All three infections are also
transmitted vertically (from mother to child) and, in
addition, represent a risk for nosocomial transmission
(transmission in a healthcare setting, if precautions for
prevention are not adhered to). Hepatitis B infection can be
prevented by vaccination. The potential vaccination
population includes IDUs and other groups who may be at
risk of infection by coming into contact with contaminated
blood or body fluids as well as groups at high risk of
transmission through unsafe sex, or even the entire general
population. In contrast, vaccination against HIV and HCV
infection is unlikely to be available in the near future. Thus,
prevention mostly depends on preventing high-risk
behaviour and encouraging behavioural change.
A substantial reduction in the incidence of drug-related
health damage, including HIV, HCV and HBV infection, is
one of the six main targets of the EU drug strategy
(2000–04). This target is also of great public health
importance in the acceding and candidate countries. To
enable evidence-based national and internationally
coordinated prevention and harm reduction responses it is
essential to monitor the level of infectious diseases among
IDUs and trends over time. The EMCDDA has been
supporting acceding and candidate CEECs to improve the
collection, analysis and dissemination of objective, reliable
and comparable information about these infections among
IDUs. Information about HIV infection among IDUs collected
by EuroHIV complements this information (European Centre
for the Epidemiological Monitoring of AIDS, 2002).
Most CEECs collect some information to enable them to
monitor trends in HIV infection prevalence among
accessible population groups of IDUs. Less information is
available about the prevalence of HCV and HBV infection.
All CEECs also collect relatively valid information on newly
diagnosed cases of HIV infection. In contrast, even when
available, most reported national incidence rates for HCV
and HBV are likely to be substantially underestimated, and
reliable information on transmission route is often
unavailable. Both the degree of under-reporting and the
availability of reliable information about transmission route
may vary greatly between countries. In addition, case
definitions may be different. Thus, for all these reasons, any
attempted comparison of reported incidence rates of newly
diagnosed HCV and HBV infections between countries is of
questionable benefit. Nevertheless, if testing and reporting
patterns are stable over time in an individual country,
monitoring reported incidence rates provides information
about trends in the burden of the disease.
The spread of HIV, HBV and HCV among IDUs is determined
mainly by injecting risk behaviour, notably sharing of
injecting equipment. However, transmission through
unprotected sexual intercourse among IDUs and their non-
IDU sexual partners is also important, especially in the case
of HIV and HBV; sexual transmission of HCV is thought to be
low. As prevention and control depend mostly on preventing
high-risk behaviour and encouraging behavioural change,
information on high-risk and risk reduction behaviour is
necessarily an integral part of drug-related infectious
diseases surveillance among IDUs. As far as HIV surveillance
is concerned, in countries with a low prevalence of infection
or concentrated epidemics, which currently includes all
CEECs (Hamers and Downs, 2003), the behavioural
component is even more important (Unaids/WHO, 2000). It
informs the design of prevention and harm reduction
interventions targeted at IDUs and also contributes to efforts
to evaluate their impact. In settings in which the prevalence
of HIV infection is low, an increase in high-risk behaviour
among IDUs is an early warning of the potential for rapid
spread. In addition, as HCV is more readily transmitted by
injecting drug use than HIV, and as HCV can easily be
transmitted through sharing of injecting equipment other than
needles and syringes, such as cotton, spoons and water,
information about HCV infection prevalence can provide
useful information about injecting risk behaviour and the
effectiveness of prevention measures. In addition, routine
surveillance information on other sexually transmitted
Chapter 3
Drug-related infectious diseases
This chapter analyses data available from the region on drug-related infectious diseases
and the measures in place to prevent their spread.
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Information about newly diagnosed cases of HIV infection
provides further evidence for large differences between the
CEECs in recent HIV infection spread among IDUs. Annual
reported incidence rates of newly diagnosed HIV infections
among IDUs per million total population are shown in
Figures 9 A and B (European Centre for the
infections, such as syphilis, can indicate high-risk sexual
behaviour among IDUs, prior to HIV transmission.
Drug-related infectious diseases can be prevented or
minimised by providing access to sterile injecting equipment
through pharmacies or community-based initiatives as well
as via outreach prevention and harm reduction
programmes. Access to information about safer drug use,
promotion of safer sex, including condom use, drug
treatment, in particular substitution with methadone or other
drugs, and immunisation against hepatitis B are further
important measures. The impact of these infections on
individuals as well as on the wider society, including
development of severe disease and prevention of secondary
transmission, can be reduced by ensuring adequate access
to counselling and testing and effective treatment of
diagnosed infections.
Information submitted by the Reitox national focal points
has been used in the preparation of this chapter, which
complements Chapter 3 of last year’s Report on the drug
situation in the candidate CEECs (EMCDDA, 2002a). If
other sources of information were used, this is noted and
the reference is cited.
Prevalence of and trends in HIV infection
Although in most CEECs IDUs have largely avoided the HIV
epidemic, HIV infection is currently spreading at an
alarmingly rapid rate among IDUs in two Baltic States:
Estonia and Latvia.
Information on HIV infection prevalence among IDUs in the
CEECs is presented in Figure 8 (for 2001 or for the last
year or period for which information was available).
Relatively high national rates of HIV prevalence among
different subgroups of IDUs tested during 2001 were
reported from Estonia (13 %) and Latvia (12 %). However,
in the capital of Estonia, Tallin, the local HIV prevalence
rate in 2001 reached the alarmingly high value of 41 %.
In Latvia and Poland, HIV prevalence among IDUs rose
above 5 % in 1998 and has remained above 5 % since.
In Lithuania, HIV prevalence increased to more than 1 %
in 1997 but remained consistently below 5 % until 2001.
In contrast, between 1996 and 2001, HIV prevalence
among IDUs remained consistently below 1 % in Bulgaria,
the Czech Republic, Hungary, Slovakia and Slovenia
(European Centre for the Epidemiological Monitoring of
AIDS, 2002). In these countries, HIV prevalence rates
among IDUs are lower than those in any EU Member State,
where levels of infection in different subgroups of IDUs vary
from about 1 % in the UK (surveys and unlinked anonymous
screening) to 34 % in Spain (routine diagnostic tests in drug
treatment) (EMCDDA, 2002c).
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Figure 8: Prevalence (%) of HIV infection among IDUs
in the CEECs, 2001 or most recent year for which an estimate
is available
NB: Data in brackets are (local) or of (unspecified) geographical coverage. If an
estimate was available only for a different year and not the year 2001, it is
marked with *. Differences between countries have to be interpreted with
caution due to different data sources or different IDU sub-populations tested
as well as different surveillance or study methods used. 
Sources: Reitox national focal points and EuroHIV for Slovakia.
Bulgaria Year: 2000; coverage: Sofia; data sources: treatment centres,
low-threshold services, needle exchanges, outreach; sample
size: 711. 
Czech Republic Year: 2001; coverage: national; data source: (public health)
laboratories; sample size: 2 169.
Estonia Year 2001; coverage: national and Tallin; data source: public
health laboratories and treatment centres, hospitals, syringe
exchanges; sample sizes: 2 078 and 964.
Hungary Year  2001; coverage: data source: those registered with the
treatment system; sample size: 315.
Latvia Year 2001; coverage: national; data source: treatment
centres; sample size: 687.
Lithuania Year 2000; coverage: not specified; data source: not specified;
sample size: 772.
Poland Year 2000; coverage: national; data source: treatment
centres, STD clinics, hospitals, testing site; sample size: 3 106. 
Romania Year 2001; coverage: national; data source: public health
departments; sample size: 2 135
Slovakia Year 2000; coverage: Bratislava, Kosice; data source:
treatment centres; sample size: 801; source of information:
EuroHIV.
Slovenia Year 2001; coverage: national; data source: treatment
centres; sample size: 559.
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Epidemiological Monitoring of AIDS, 2002; Hamers and
Downs, 2003). During the last few years these rates have
increased most dramatically in Estonia but also quite
substantially in Latvia. In 2001, the rates reached 970 per
million population in Estonia and 271 per million
population in Latvia (an increase of 282 % and 67 %,
respectively, in comparison with the previous year). These
rates are much higher than the total rates of new HIV
diagnoses (not just among IDUs) reported from any EU
Member State, among which overall HIV infection rates in
2001 varied from 16 per million population in Germany to
251 per million in Portugal (European Centre for the
Epidemiological Monitoring of AIDS, 2002). In fact, some
east European countries are threatened by the most rapidly
developing HIV epidemic in the world. The reported rates of
newly diagnosed HIV infections among IDUs per million
general population for the year 2001 were considerably
lower in Lithuania and Poland, 15 and 6 per million
population respectively, and much lower still, below 1 per
million population, in all other CEECs.
Reflecting earlier spread of HIV infection among IDUs,
annual rates of AIDS incidence among IDUs have been
rising in Latvia and reached 12 per million total population
in 2001 (European Centre for the Epidemiological
Monitoring of AIDS, 2002). Between 1997 and 2001
the reported incidence of AIDS among IDUs stabilised at
just under 2 per million population in Poland and remains,
for the time being, below 1 per million population in all
other CEECs, including Estonia.
Prevalence of and trends 
in hepatitis C infection
Chronic infection with HCV, which occurs in most, but not
all, individuals who have been infected, may have serious
health consequences, including severe liver damage and
premature death. Available information about the
prevalence of antibodies to HCV among IDUs for 2001 or
the last year or period for which the information was
available is presented in Figure 10. For all CEECs for which
prevalence estimates are available, the data indicate a
much higher prevalence of hepatitis C infection than of HIV
infection. Thus, in the near future, at least in some CEECs,
hepatitis C infection may present a greater challenge for
control among IDUs than HIV infection.
The prevalence of antibodies to HCV among IDUs in the
Czech Republic, Hungary, Slovakia and Slovenia varies up
to 40 %. This indicates much lower levels of hepatitis C
infection among IDUs in these four countries than in any EU
Member State, where rates of HCV infection among IDUs
vary between 40 and 90 %, except in the UK, where the
rate is lower (EMCDDA, 2002c). In Bulgaria, Estonia, Latvia
and Lithuania, the estimated prevalence rates of HCV
infection are higher and closer to those in EU Member
States. Some CEECs collect HCV surveillance information
among IDUs that enables monitoring of trends. In the last
few years, the prevalence of antibodies to HCV among
IDUs has remained fairly stable in Slovenia and has fallen
in Lithuania as well as in one subpopulation of IDUs in the
Karvina district in the Czech Republic. In contrast, the rate
has increased in Sofia, Bulgaria, from below 60 % during
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Figure 9: Reported newly diagnosed HIV infection cases among
IDUs per million population in the CEECs, 1997–2001
A
B (1)
(1) Estonia and Latvia not shown.
Source: Adapted from European Centre for the Epidemiological Monitoring of AIDS
(2002).
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Estimates of the prevalence of HCV infection among new
IDUs who have been injecting illicit drugs for less than two
years are available for only two CEECs, the Czech
Republic, where the prevalence is below 20 %, and
Slovenia, where it ranged from 0 % in 1996 to a peak of
13 % in 1999 before falling again, to 7 %, in 2001.
These HCV prevalence estimates are much lower than
corresponding estimates reported from EU countries, where
they are generally 40 % or higher (EMCDDA, 2000c).
Information about newly diagnosed cases of HCV infection
among IDUs may enable national trends to be monitored
in countries with stable testing patterns among IDUs as
well as unchanging reporting patterns. For example, it was
reported from the Czech Republic that the annual incidence
of acute HCV infection among IDUs declined from 21 per
million general population in 1999 and 2000 to 16 per
million in 2001, suggesting a recent decrease in high-risk
injecting behaviour among IDUs.
Hepatitis B infection
Information about the prevalence of HBsAg (the serological
marker that indicates that HBV infection is still present)
among IDUs was available only for Bulgaria, Hungary and
Romania; information about the prevalence of antibodies
to HBV was available from the Czech Republic, Estonia,
Latvia, Lithuania, Slovakia and Slovenia (Figure 11).
The presence of antibodies to HBV (HBcAb, HBsAb) may
indicate either current or previous infection, or vaccination
against hepatitis B. Thus, differences in vaccination
practices between countries must be taken into account
when comparing information about the prevalence of
antibodies to HBV among IDUs. The proportion of IDUs who
have none of the HBV markers (HBcAb, HBsAb, HBsAg) in
their blood indicates those who are still at risk of infection
and thus represents the potential vaccination population. If
information on the prevalence of some or all markers of
HBV infection were available from all CEECs, the data
would be much easier to interpret and compare.
Bulgaria, the Czech Republic, Lithuania and Slovenia collect
HBV surveillance information that enables monitoring of
trends. In most cases, it is difficult to conclude whether
these trends reflect true changes in prevalence rates. In
Bulgaria, for example, the prevalence of HBsAg among
tested IDUs in Sofia gradually declined from 16 % in 1996
to 5 % in 2001. Possible explanations for this finding, other
than a true decrease in prevalence, include changes in
access to testing and criteria for testing (e.g. more IDUs
without clinical signs of infection tested more recently),
changes in the characteristics of IDUs (e.g. an increase in
the period 1996 to 1998 to above 70 % during the period
1999 to 2001. These trends may reflect true changes in
prevalence rates. However, we should be cautious in
drawing such a conclusion in all cases. The differences may
also reflect changes in testing patterns or changes in some
characteristics of the mix of IDU subpopulations tested, for
example differences in the history or duration of injecting,
or some other methodological inconsistencies over time.
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Figure 10: Prevalence (%) of antibodies to hepatitis C among 
IDUs in the CEECs, 2001 or most recent year for which an estimate
is available
NB: n.a. = not available. Data in brackets are (local) or of (unspecified) geo-
graphical coverage. If an estimate was available for a different year and not
the year 2001, it is marked with *. If several estimates were available, range
is given. Differences between countries have to be interpreted with caution
due to different data sources or different IDU sub-populations tested as well
as different surveillance or study methods used.
Sources: Reitox national focal points.
Bulgaria Year 2001; coverage: Sofia; IDU sub-populations: treatment
centres, needle exchanges, low threshold services, outreach;
sample size: 435.
Czech Republic Year 2001; coverage: Karvina district and Prague; data
sources: low-threshold and methadone substitution; sample
sizes: 38 and 60.
Estonia Period 1994–95; coverage: Tallin; data source: not speci-
fied; sample size: 57.
Hungary Period 2001; coverage:  data source: those registered with
the treatment system; sample size: 315.
Latvia Year 2001; coverage: Riga; data source: syringe exchange;
sample size: 261.
Lithuania Year 2000; coverage: national; data source: not specified;
sample size: 693.
Romania Year 2001, coverage: Bucharest; data source: drug treatment
centres; sample size: app. 1 200.
Slovakia Year 2001; coverage: Bratislava; data source: first treat-
ment demand; sample size: 183.
Slovenia Year 2001; coverage: national; data source: treatment cen-
tres; sample size: 554.
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younger users or users who have been sharing injecting
equipment for a shorter period, or changes in the patterns
of equipment sharing with IDUs who are not HbsAg
carriers) and increased access to, or uptake of, vaccination
against hepatitis B.
Tuberculosis and other diseases
Information on the burden of tuberculosis (TB), sexually
transmitted infections (STIs) and some other serious health
problems that are associated with injecting drug use is
scarce. Although in some CEECs TB may present a
substantial health problem among IDUs, with reported
incidence rates much higher than in the general population
and many HIV/TB co-infections (Latvia, Romania), in others
TB among IDUs does not seem to be a major problem. In
Slovenia, for example, among 372 acute TB cases
diagnosed in 2001 (18.7 per 100 000 population), only
two had a history of injecting drug use.
Drug-related infectious diseases’
risk behaviour
Although surveillance of high-risk injecting and sexual
behaviour should ideally be an integral part of drug-related
infectious diseases surveillance among IDUs, such
information is scarce. Systematic collection of comparable
information on two high-risk injecting behaviour indicators
(sharing needles and syringes, lifetime and last 30 days
prevalence) was promoted by the Pompidou Group project
on treatment demand. The project was designed to monitor
trends relevant to problem drug use by collecting
comparable data at the point of treatment demand. A total
of 23 European cities participated, including some in the
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Figure 11: (A) Prevalence (%) of HBsAg among IDUs in the CEECs, 2001 or most recent year for which an estimate is available
(B) Prevalence (%) of antibodies to HBV among IDUs in the CEECs, year 2001 or most recent year for which an estimate is available
Figure 11A: HBsAG Figure 11B: HBV
NB: Data in brackets are local. If an estimate was only available for a different year and not the year 2001, it is marked with *. If several estimates were available, the range
is given. Differences between countries have to be interpreted with caution due to different data sources or different IDU sub-populations tested as well as different sur-
veillance or study methods used. 
Sources: Reitox national focal points.
Bulgaria Year 2001; coverage: Sofia; data source: treatment centres, needle exchanges, low threshold services, outreach; sample size: 689.
Czech Republic Year 2001; coverage: Karvina district and Prague; data sources: low-threshold and methadone substitution; sample sizes: 39 and 60.
Estonia Period 1994–95; coverage: Tallin; data sources: not specified; sample size: 57.
Hungary Period 2001; coverage: data source: those registered with the treatment system; sample size: 315.
Latvia Year 2001; coverage: Riga; data source: syringe exchange; sample size: 261.
Lithuania Year 2000; coverage: national; data source: not specified; sample size 698.
Romania Year 2000; coverage: Bucharest; data source: drug treatment centres; sample size: approximately 1 200.
Slovakia Year 2001; coverage: Bratislava; data source: first treatment demand; sample size: 101.
Slovenia Year 2001; coverage: national; data source: treatment centres; sample size: 550.
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received drugs in exchange for sex in the past month and
21 % had received money for sex. Seventy-two per cent of
respondents perceived themselves to be at risk for HIV
infection, but only 14 % believed themselves to be at risk
for hepatitis (HAV, HBV or HCV). Eighty-six per cent had
received preventative information or a protective device at
some time in their life, 47 % had been tested for HIV and
40 % for any of the hepatitis viruses, and 14 % had been
vaccinated against HBV.
The results of several other studies in CEECs were reported
in the 2002 report on the drug situation in the candidate
CEECs (EMCDDA, 2002a).
Harm reduction
Access to sterile injection equipment and information on
safer drug use is essential to minimise the spread of drug-
related infectious diseases among IDUs. In addition,
promotion of safer sex, including the use of condoms,
among IDUs as well as with non-users helps to contain
sexual transmission of these infections.
In all CEECs for which information is available, sterile
injection equipment can be purchased from pharmacies
without a prescription. In 2001, in most CEECs the price of
syringes in pharmacies was EUR 0.1. The exceptions were
Estonia, where the price was lower (EUR 0.06), and
Slovenia and Romania, where it was higher (EUR 0.14 and
up to EUR 0.2 respectively). Only in Slovenia and Latvia
can syringes also be exchanged or distributed through
CEECs. The proportions of current IDUs (i.e. who had
injected in the last month) who reported sharing needles
and syringes in the month prior to treatment demand are
shown in Figure 12 for three selected cities for a period of
several years (Pompidou Group, 1999). Results are shown
only for those cities that could supply data for at least 100
IDUs each year. Although validity is obviously a concern
with self-reported information, the results are informative.
Such an approach is clearly appropriate for monitoring
trends and has the potential to reflect changes in the access
of IDUs to sterile injecting equipment, e.g. through syringe
exchange programmes (SEPs). The proportion of IDUs who
reported sharing injecting equipment was disturbingly high
and does not provide support for the desired beneficial
effect of SEPs. Data collection was stopped in 2001.
Various one-off research projects on high-risk injecting and
sexual behaviour among IDUs have been conducted in the
CEECs. It is difficult to use the results of such studies to
draw comparisons between countries, as surveyed
populations, data collection methods and time frames may
all differ, as may the high-risk behaviour indicators
measured as well as the presentation of results. However,
such studies are very informative and extremely valuable
for the design of prevention and harm reduction
interventions among IDUs in the specific local context, and
can also contribute to evaluation of their impact.
In 2001, a major survey of injecting and sexual risk
behaviour among IDUs, combined with testing for HCV and
HBV infection, was conducted in Ida-Virumaa, a region of
Estonia. A total of 2 930 IDUs who visited different SEPs
completed the survey questionnaire. The overall survey
response was very high (98 %). Sharing syringes was
reported by 45 % of clients. Purchasing syringes from
pharmacies was reported by 31 %. Fifty per cent of
respondents admitted to having at least four sexual partners
in the preceding year but only 15 % claimed to use
condoms regularly.
Smaller-scale studies have been carried out in many other
CEECs. For example, in 2001, 95 IDUs were interviewed at
several different locations in Budapest. They were asked
questions about high-risk injecting and sexual behaviour,
including sex with non-IDUs, and about their perception of
their risk of contracting infections, previous exposure to
preventative messages or interventions, access to testing for
HIV, HCV and HBV and whether they had been vaccinated
against hepatitis B. Sharing needles and syringes during the
previous month was reported by 33 % and sharing of other
paraphernalia was admitted by 41 %. More than one
sexual partner during the preceding month was reported by
34 % of sexually active IDUs and exclusively non-IDU
partners by 26 %. Twenty-eight per cent reported having
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Figure 12: Proportion of current IDUs (injected last month) who
reported sharing needles and syringes within the month prior to
treatment demand, 1994–97 (Pompidou Group multi-city project
on treatment demand)
Source: Adapted from Pompidou Group (1999).
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pharmacies. Not a single CEEC reported the existence of a
national programme to support the sale of syringes to IDUs
in pharmacies, although Estonia and Latvia reported
sporadic efforts to provide at least some training for
pharmacists with the aim of raising awareness of the need
to prevent drug-related infectious diseases among IDUs.
With the exception of Lithuania, no CEEC reported the
distribution of prevention information targeted specifically
at IDUs through pharmacies. Information on the numbers
of syringes sold to IDUs through pharmacies would be
very valuable in assessing the overall access of IDUs.
The Czech Republic reported that in 2001 approximately
one million syringes were sold to IDUs through pharmacies
(97.8 syringes per 1 000 total population). National
estimates of the proportion of IDUs who purchase sterile
injecting equipment through pharmacies are generally not
available, except in Hungary, where the figure in 2001
was approximately 30–40 %.
All CEECs have in place some community-based or
outreach harm reduction programmes that provide access
to sterile injecting equipment and information on safer drug
use and often also promote safer sex, including the
distribution of condoms. In Poland, the ‘National
programme for prevention and counteracting of AIDS’,
adopted in 1988, recommended the introduction of SEPs,
and the largest non-governmental organisation, Monar,
started distribution in 1988 (UN ODCCP/Unaids, 2003). In
1989, the Minister for Health and Social Welfare required
provincial head physicians to appoint special centres to
initiate free distribution of sterile injecting equipment and to
allocate appropriate financial resources for that purpose.
Slovenia and the Czech Republic implemented SEPs in
1992 and 1993 respectively, to be followed by several
central European countries in the mid-1990s: Slovakia in
1994, Bulgaria and Hungary in 1995 and Romania in
1998. Among the Baltic States, Lithuania and Estonia were
the first to introduce SEPs, in 1996 and 1997 respectively,
followed by Latvia in 1999. In CEECs for which information
is available, the number of syringes exchanged or
distributed in 2001 varied from 8.5 per 1 000 total
population in Hungary to 115.3 per 1 000 in the Czech
Republic. Thus, in the Czech Republic in 2001, an
estimated 213.1 syringes per 1 000 population were either
obtained through SEPs or bought in pharmacies.
The numbers of syringes exchanged or distributed among
IDUs per 1 000 population in 2001 or the last year for
which information was available are shown in Figure 13.
The wide differences in rates are informative about the
coverage of SEPs. More meaningful figures would take
account of estimated numbers of IDUs; however, the
accuracy and comparability of available IDU prevalence
estimates vary substantially between CEECs. In several
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Figure 13: Total estimated numbers of syringes exchanged or
distributed among IDUs per 1 000 general population in CEECs,
year 2001 or most recent year for which an estimate is available
NB: If an estimate was available for a different year and not year 2001, it is marked
with *. Differences between countries have to be interpreted with caution due
to different availability of information and possible validity constraints. 
Sources: Reitox national focal points. 
Bulgaria Year: 2001; coverage: 5 programmes, in Sofia (2), Pleven,
Plovdiv, and Burgas; year of implementation of the first pro-
gramme: 1995; ratio of exchanged versus distributed
syringes: not available.
Czech Republic Year 2001; coverage: national (65 sites); year of imple-
mentation of the first programme: 1992; ratio of exchanged
versus distributed syringes: 1/1.
Estonia Year 2000; coverage: 20 programmes, in Tallin, Tartu,
Narva, Sillamae, Kohlta-Jarve, Johvi, Kivioli; year of imple-
mentation of the first programme: 1997; ratio of exchanged
versus distributed syringes: not available.
Hungary Year 2001; coverage: 7 programmes, in Budapest (3),
Miskolc, Veszpren, Pecs, Szeged; year of implementation of
the first programme: 1995; ratio of exchanged versus dis-
tributed syringes: not available.
Latvia Year 2001; coverage: 7 programmes, in Riga, Jurmala,
Tukums, Liepaja, Olaine; year of implementation of the first
programme: 1999; ratio of exchanged versus distributed
syringes in 2001: 1/0.89.
Lithuania Year 2000; coverage: in 5 cities; year of implementation of
the first programme: 1996; ratio of exchanged versus dis-
tributed syringes: not available.
Poland Year 2000; coverage: not available; year of implementation
of the first programme: not available; ratio of exchanged ver-
sus distributed syringes: not available.
Romania Year 2001; coverage: 4 programmes, in Timisoara (Timisiensis
XXI), Bucharest (ARAS, ALIAT, Open doors), some other cities
(ARAS); year of implementation of the first programme:
1998; ratio of exchanged versus distributed syringes in
2001: 2.88/1.
Slovakia Year 2001; coverage: 4 programmes, in Bratislava (3),
Banska Bystrica (1); year of implementation of the first pro-
gramme: 1994; ratio of exchanged versus distributed
syringes: not available.
Slovenia Year 2001; coverage: 3 programmes at least, in Ljubljana,
Celje, Zalec (last two through pharmacies); year of imple-
mentation of the first programme: 1992; ratio of exchanged
versus distributed syringes in 2001: 1/0.80.
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several countries (Bulgaria, the Czech Republic, Estonia,
Hungary, Latvia, Romania and Slovenia). SEPs are less
reliable as a source of condoms than of sterile injecting
equipment. However, condoms can be purchased readily
in all CEECs, the price varying from EUR 0.3 to EUR 0.7
each in countries which provided this information
(the Czech Republic, Hungary, Latvia, Slovenia).
Substitution treatment
Substitution treatment is available to IDUs in all CEECs;
however, availability varies considerably. In 2001 in
Slovenia, 679 IDUs per million total population were on
methadone maintenance, but the corresponding rate in
Estonia was only 3.6. Total estimated numbers of IDUs
receiving methadone substitution treatment per million
population in 2001 or the most recent year for which
an estimate is available are shown in Figure 15. With
the possible exception of Slovenia, access to methadone
substitution is clearly insufficient. The next highest rates
were in Slovakia and the Czech Republic, but here the
numbers of drug users receiving methadone were
approximately 10–20 times lower. Like coverage of SEPs,
more meaningful rates would take account of the estimated
numbers of IDUs.
Information on trends was available from some CEECs. It is
encouraging that from 1997 to 2001 the numbers of clients
on methadone increased from 464.2 per million population
to 679.3 in Slovenia, from 4.1 to 66.7 per million in
Slovakia and from 2.1 to 3.6 per million in Estonia.
Information on the extent to which substitution treatment is
available through general practitioners in the CEECs, if at
all, is not available. Thus, caution is needed when
interpreting available information on substitution with
methadone as availability of substitution treatment in
general. In Slovakia, for example, buprenorphine can be
prescribed by general practitioners, indicating greater
availability of substitution treatment than suggested by
methadone substitution data only.
Vaccination against hepatitis B
Vaccination against hepatitis B is, in principle, available to
IDUs in most CEECs. In practice, coverage is far from ideal
and is very low in most countries. Information about shorter
basic vaccination schedules, which are sometimes used to
increase completion rates among IDUs, is scant, although
the Czech Republic reports the use of such schedules during
HBV epidemics. Vaccination of IDUs against HBV is not
usually covered by health insurance schemes, except in
Slovenia, where most clients on methadone substitution who
are in regular contact with primary healthcare services
have therefore been vaccinated. In the future, all IDUs will
CEECs for which information is available, the increase
in the numbers of sterile syringes exchanged or distributed
in recent years indicates a gradual improvement in the
availability of sterile injecting equipment (Figure 14).
This trend is encouraging, but still availability does not meet
demand. If demand for sterile exchanges were satisfied
(the ideal situation), trends in exchanged or distributed
sterile injecting equipment would reflect increases or
decreases in demand, and could provide a means of
monitoring changes in the extent of injecting drug use.
In most CEECs for which information is available (Bulgaria,
Hungary, Latvia, Slovenia), there are no major limitations
on SEPs, such as requiring a used needle in exchange for
a new one, and sterile syringes are distributed relatively
liberally. In contrast, in Estonia, one-for-one exchange is
strictly enforced. Information on the ratio of sterile syringes
supplied in exchange for used ones in SEPs in 2001 was
available for only three countries and was 1 to 0.98 in
Latvia, 1 to 0.80 in Slovenia and 1 to 0.35 in Romania.
The perception that funding for SEPs is inadequate and
geographical coverage insufficient is almost universal,
although in most CEECs some SEPs have been established
outside the capital cities.
Promotion of safer sex among IDUs, including the
promotion of condom use, should be an integral part of
any community-based or outreach harm reduction
programme for IDUs. Nevertheless, information on such
interventions, for example on the numbers of condoms
distributed, is less readily available, although it is known
that condoms have been distributed to IDUs through SEPs in
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Figure 14: Trends in estimated numbers of syringes exchanged or
distributed among IDUs per 1 000 general population in selected
CEECs, 1997–2001
Source: Reitox national focal points.
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have been vaccinated, as immunisation against hepatitis B
has been introduced for the general population in all
CEECs. In many countries, the basic immunisation series
should be completed within the first year of life, but in
some, i.e. the Czech Republic, Estonia, Hungary, Slovenia
and Romania, older age groups are targeted, either
exclusively or in addition to children in the first year of life
(at age 12, 13, 14, 6 and 9 respectively). The estimated
coverage in 2001 was generally high, ranging from 90 %
in Estonia to as high as 99 % in the Czech Republic, Poland
and Slovakia (WHO, 2003). Thus, for example, in the
Czech Republic, where 12-year-olds have been vaccinated
since 2001, the vast majority of 16-year-old adolescents
will have been vaccinated by 2005, and in Slovenia,
where immunisation of six-year-olds was introduced
in 1998, this target will be achieved by 2008.
Access to counselling and testing
Many CEECs provide access to anonymous HIV counselling
and testing, but testing policies and practices vary.
In Lithuania, for example, a Ministry of Health decree makes
HIV testing mandatory for all known IDUs at least once per
year. In contrast, in Slovenia, optional confidential testing is
offered annually to all clients on methadone maintenance.
Estonia reports that testing for HCV infection, available
previously, has now been stopped as all available resources
have been reassigned to diagnosing HIV infection.
Access to treatment
Good comparable information on IDUs’ access to treatment
for HIV and HCV is not readily available. In all CEECs
for which information is available, treatment, if provided,
is free of charge. Generally, access to good-quality
treatment for HIV or HCV infection seems to be very limited.
Highly active anti-retroviral therapy (HAART) for 
all HIV-infected IDUs seems to be readily available only
in the Czech Republic, Hungary and Slovenia.
Summary and conclusions
• Drug-related infectious diseases among injecting drug
users (IDUs), i.e. HIV, HCV and HBV infection and some
other serious diseases, including TB and sexually
transmitted diseases, are key public health problems
arising from drug use-related harm. The high
prevalence of these infections among IDUs also
represents a potential threat for the spread in the
general population.
• To reduce substantially the incidence of drug-related
health damage, including HIV, HCV and HBV infection,
is one of the six main targets of the EU drug strategy
(2000–04).
• Recently, HIV infection has spread among IDUs in
Estonia and Latvia at an alarming rate, and in 2001
HIV prevalence among a group of IDUs in Tallin
reached 41 %. HIV prevalence remained below 20 %
in Poland, below 5 % in Lithuania and below 1 % in all
other CEECs, the last figure being lower than in any
EU Member State.
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Figure 15: Total estimated numbers of IDU clients on substitution
treatment per million general population in the CEECs, year 2001
or most recent year for which an estimate is available
NB: If an estimate was available for a different year and not year 2001, it is marked
with *. Differences between countries have to be interpreted with caution due
to different availability of information and possible validity constraints. 
Sources: Reitox national focal points. 
Bulgaria Year 2002; first programme in 1995; coverage 1 site in
Sofia; substitution drug: methadone.
Czech Republic Year 2001; pilot programme: approved programmes started
in 1997; coverage: 8 sites: in Prague and in 7 other cities;
substitution drug: methadone.
Estonia Year 2001; first programme: in 1997; coverage: 2 sites;
substitution drug: methadone.
Hungary Year 2001; first programme: 2001; coverage 4 sites; sub-
stitution drug: methadone; data on individual prescriptions
since 1993 not included.
Lithuania Year 2000; first programme: 1995; coverage: 4 cities; sub-
stitution drug: methadone.
Romania Year 2001; first programme: information not available; sub-
stitution drug: methadone.
Slovakia Year 2001; first programme: 1997; coverage: 1 site, in
Bratislava; substitution drug: methadone; bupronorphine
can be prescribed by any general practitioner.
Slovenia Year 2001; first programme in 1990; coverage: 17 sites,
countrywide; substitution drug: methadone.
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• Good comparable information on IDUs’ access to testing
for HIV, HCV and HBV as well as treatment for HIV
and HCV is not readily available. Testing policies and
practices vary between CEECs. In the majority of
CEECs, access to high-quality treatment for either
HIV and HCV infection seems to be very limited.
• Reitox national focal points in CEECs should continue
to support further development of infectious diseases’
indicators at a national level, the introduction of
evidence-based measures and the collection of data
on the type and coverage of specific responses.
• Evidence has been accumulating that the introduction
of harm reduction programmes with good coverage,
as well as provision of substitution treatment that is
easy to access, contributes to lower levels of 
drug-related infectious diseases (Hurley et al., 1997).
It is known that HIV infection, once introduced in
the IDU community, may, depending on the level of
high-risk behaviour, spread extremely rapidly
(Unaids/WHO, 2000). This is currently occurring in
Estonia and Latvia. The introduction of harm reduction
interventions with good coverage contributes to lower
• In many CEECs (Bulgaria, Estonia, Latvia, Lithuania),
the prevalence of antibodies to HCV among IDUs is
higher than 60 %, as it is in most EU Member States.
In some others (the Czech Republic, Hungary, Slovakia,
Slovenia), although still high, the figure is below 40 %.
• Reasons for variation in the burden of drug-related
infectious diseases between countries include differences
in high-risk behaviour patterns, the time of introduction
of infections, access of IDUs to sterile injecting
equipment, information on safer drug use and treatment
programmes (notably substitution treatment) and
coverage of hepatitis B vaccination programmes.
It is very difficult to isolate the individual effects of
these and other potential factors.
• Prevention of HIV and HCV infections among IDUs
mostly depends on preventing high-risk injecting and
sexual behaviour and encouraging behavioural change.
Thus, high-risk behavioural surveillance that monitors
changes in such behaviour over time should be
an integral part of drug-related infectious diseases
surveillance. Unfortunately, at present, such information
is scant.
• In all CEECs for which information is available, sterile
injection equipment can be purchased in pharmacies
without prescription and community-based or outreach
harm reduction programmes that provide access to
sterile injecting equipment are in place. However,
national programmes to support easy access to syringes
through pharmacies do not exist, and insufficient
funding for and geographical coverage of SEPs is
almost universal. Similarly, although substitution
treatment programmes (mostly methadone maintenance,
which has proved effective in reducing unsafe injecting)
do exist, availability is even more limited.
• In principle, vaccination against hepatitis B is available
to IDUs in all CEECs, but the coverage is far from ideal.
However, vaccination coverage among IDUs is expected
to improve in the future, as immunisation of the general
population against hepatitis B has been introduced in all
CEECs. Targeted vaccination programmes should be
implemented in the short term to protect current cohorts
of injectors, while coverage of IDUs should be
continuously monitored.
• Extensive harm reduction interventions are essential
in lowering the burden of HIV, HCV and HBV infections.
In countries where widespread introduction of harm
reduction interventions preceded the introduction
of HIV infection, the future burden of AIDS among IDUs,
as well as among the general population, will probably
be much lower than elsewhere.
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Further challenges for meaningful data collection
Evidence-based national and internationally coordinated
prevention and harm reduction interventions, aimed at
reducing the incidence of drug-related HIV, HCV and HBV
infection among IDUs and minimising the risk of spread of
these infections to the general population, requires improved
collection, analysis and dissemination of objective, reliable
and comparable information about the burden of and trends
in drug-related infectious diseases among IDUs. Sufficient
resources should be allocated at both the international and
national level, and options for more intensive collaboration
between relevant institutions, in particular those specialising
in drug use and infectious diseases, should be explored.
Regular, harmonised routine information collection on drug-
related infectious diseases, complemented by data collection
on relevant behavioural indicators and in-depth studies,
should be encouraged as an integral part of infectious
disease surveillance among IDUs.
With regard to prevention of drug-related infectious
diseases among IDUs, the provision of objective information
about risks, risk behaviour education, vaccination against
hepatitis B, methadone maintenance and other types of
treatment and access to sterile syringes and other injecting
equipment is important and should be monitored and
evaluated against the background of infectious disease
prevention as a concrete policy target.
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HIV infection prevalence at a later stage of the
epidemic. In Poland, the timely introduction of SEPs
(in 1988) is assumed to have been responsible, at least
in part, for the low number of cases of HIV infections
occurring among IDUs (UN ODCCP/Unaids, 2003).
HIV infection has not yet begun to spread rapidly in
many CEECs. Harm reduction interventions and widely
available substitution treatment will, if introduced
promptly, before HIV infection takes hold of the IDU
population, result in a lower prevalence of HIV infection
in the future than if interventions are introduced only
once infection has started to spread. Those countries in
which extensive harm reduction interventions have
preceded the introduction of HIV infection in the IDU
community, for example the Czech Republic and
Slovenia, have invested well.
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(21) Information was not available from the ELDD network for Slovenia for this section.
(22) Slovakia (1996), the Czech Republic (1999), Latvia (1999), Bulgaria (2000), Romania (2000), Estonia (2002), Lithuania (2003) and Hungary (1999, 2003). 
(23) In preparation at the time of writing.
Introduction
This chapter is based on the Reitox national reports, the
official drug strategies and the legal texts included in the
European legal database on drugs (ELDD)
(http://eldd.emcdda.eu.int). The chapter is also the fruit
of a close collaboration within the national focal points
and other professionals in the acceding and candidate
countries.
Owing to the limitations of the data and information
available, the chapter is confined to a description of the
formal arrangements currently in place in the countries
reviewed. More in-depth aspects, such as implementation
of laws, assessment of national strategies or effectiveness
of drug coordination mechanisms, are therefore outside
the scope of this review. Clearly, comparing only the formal
structures of drug policy, i.e. laws, plans and coordination
systems, precludes a more accurate analysis and can mask
the differences between those countries in which official
positions are effectively translated into practices and those
in which good intentions remain ‘on paper’. Only accurate
case studies can reveal the extent of implementation of
a national drug strategy; however, taking into account
the above-mentioned constraints, it is important, as a first
step, to report on formal structures, recording the
commitment of governments to face the drug problem.
This chapter discusses the 13 EU acceding and candidate
countries to the EU. However, because of the scarcity
of the available information, the principal focus is on
the 10 countries of central and eastern Europe,
confining consideration of Malta, Cyprus and Turkey
to the legislative aspects.
Legislation (21)
Development of laws
Since 1991, most of the acceding and candidate countries
have been active in making major changes to their
legislation in order to address the drug problem. As well as
being in conformity with the UN conventions, before 1990
the drug laws in a number of the countries concerned seem
to have been similar to the legislative framework of
the former Soviet Union. This effectively provided a
relatively homogeneous basis from which each country
is independently developing its national legislation.
In these countries, changes or consolidation of legislation
in the drugs field have been particularly noticeable since
the mid-1990s.
Most acceding and candidate countries have chosen to
address the offences of drug possession and trafficking in
their penal code. In the last 10 years, seven (22) have
replaced or significantly revised their penal codes to
include revision of drug offences and/or penalties. Among
those countries that have specific laws to describe drug
offences, Romania and Poland have passed comprehensive
new laws in the past five years, and Malta’s main drug
control laws, which date back several decades, last
underwent a major update in 1985.
Despite their comparatively recent changes of legislation,
the Czech Republic and Hungary have already undertaken
selective studies to try to assess the implementation of these
laws. In the Czech Republic, the preliminary results of these
studies showed that the 1999 criminalisation of ‘possession
of amounts greater than small’ brought more social costs
than benefits — at a minimum, the situation would have
been aided by definition of the threshold quantity, for
which prosecutorial guidelines were issued in 2000,
and identification of different categories of drugs based
on harm (23). In Hungary, the criminalisation of any use,
again in 1999, was considered to have had more negative
consequences than positive effects, and so this specific
offence was removed in 2003.
Legal attitudes to drug users
Three countries (Cyprus, Malta, Turkey) consider use per se
to be a criminal offence, although in one (Malta) the
offence applies only to the use of prepared opium. Between
1999 and 2003, use was also an offence in Hungary, but
this was changed following evaluation, as reported above.
A number of countries (Romania, Estonia, Latvia and
Chapter 4
Characteristics of drug strategies in the acceding and candidate countries
This chapter provides a descriptive review of the main instruments of drug policy, namely laws,
strategies and coordination arrangements in the field of drugs. 
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noted, in Bulgaria and Hungary the motive is generally not
taken into account in the description of the offence. In
Hungary, offences are distinguished by small or large
quantities of drugs, while in Bulgaria a wide range of
sentences can be imposed for all illegal acts related to
possession or supply. The law in Bulgaria provides for a
separate offence only if the offender is drug dependent and
the quantity possessed suggests intention of personal use.
Small-scale selling to finance one’s own addiction is
addressed by specific legal provisions in Hungary, and
certain provisions might cover this in Estonia and Poland.
However, it would require a more detailed survey on the
implementation of the law to clarify whether or not these
provisions are used in such circumstances, or if this is taken
into account when sentencing for a trafficking offence.
Most of the acceding and candidate countries provide for
separate offences of cultivation and of trafficking
(possession or supply for sale or benefit, which also
normally includes production). In some countries (including
Estonia, Latvia, Lithuania and Poland), cultivation attracts a
lesser maximum sentence than production or trafficking, but
in Bulgaria a group formed for the purposes of production
or cultivation, rather than trafficking, could attract the most
severe sentences.
Finally, in many of the acceding and candidate countries
the law accommodates specific increases in sentences when
a group or criminal organisation is involved in drug
trafficking. This may take the form of aggravating
circumstances or a separate offence.
Penalties for drug possession and trafficking in the
acceding and candidate countries are shown in Table 4.
National drug strategies
Current national drug strategies
The information in this section comes from the 10 candidate
or acceding countries of central and eastern Europe (CEECs),
i.e. Bulgaria, the Czech Republic, Estonia, Hungary, Latvia,
Lithuania, Poland, Romania, Slovakia and Slovenia.
Information from Malta, Cyprus and Turkey was not
available. National drug strategies are in place, or are in the
process of being adopted, in all 10 CEECs. This trend to
develop policy plans, also visible at EU level, shows that the
CEECs are increasingly planning and committing to the
implementation of drugs-related activities as part of a wider,
more comprehensive approach that embraces a global
national drug policy (Table 5). Indeed, in many cases,
drug strategies in the CEECs appear to have drawn on
Lithuania) prohibit consumption of controlled substances
without prescription, but this is usually punishable by an
administrative sanction for a first offence.
There are clear differences between countries in the
interpretation of ‘possession of small amounts of drugs
for personal use’. Of the nine countries (Bulgaria, Cyprus,
Hungary, Lithuania, Malta, Poland, Romania, Slovakia and
Turkey) that treat this as a criminal offence, four (Cyprus,
Malta, Romania and Turkey) criminalise all unauthorised
possession regardless of quantity and two (Bulgaria and
Hungary) do not consider the intent behind the possession.
Poland and Lithuania have chosen to establish this act as
a criminal offence only recently, when previously it was
an administrative offence. These countries may recognise
mitigating circumstances to reduce the punishment.
Three countries (the Czech Republic, Estonia and Latvia)
maintain administrative measures to punish the first offence
of possession of a small quantity of drugs for personal use.
This is similar to the Soviet code, which held that possession
of a small quantity of any narcotic drug for personal use
was an administrative rather than a criminal offence
(Babayan, 1990). These countries nevertheless retain
the option to prosecute the offender under the criminal
code if the offence is repeated or if the quantity of drugs
is greater than small. All have set specific limits in their
legislation or guidelines for prosecutors to indicate the
maximum amount of a ‘small quantity’, whereas many
countries in the EU leave this to the discretion of the judge
or prosecutor (ELDD, 2003).
It is interesting to note that a number of acceding and
candidate countries have moved towards criminalising
possession for personal use, or use itself, over the past
12 years, while the most recent drug law modifications
within the European Union countries have addressed
the same question in a different way (ELDD, 2002).
Trafficking
As stated above, in some of the acceding and candidate
countries a ‘small quantity’ of drugs is clearly defined in
law, and possession of more than this amount is considered
a crime, although not necessarily as trafficking. In three
countries (the Czech Republic, Estonia and Latvia), the
criminal offence committed in possessing more than a small
amount of drug varies depending on intent, and the
sentences that can be imposed are more severe if the
reason for possession is sale or profit. For example, in
Poland, the maximum penalty for possessing a considerable
quantity of drugs is lower than the maximum penalty for
supplying any quantity with intent to benefit. As already
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Table 4: Penalties for drug possession and trafficking in the acceding and candidate countries
(1) Countries may have offences addressing any possession/possession for personal use/possession without intent of trafficking.
(2) Many countries have more than one offence that might describe the behaviour of the offender, with different sanctions. The prosecutor chooses which is the most
appropriate in each case.
(3) Here, trafficking describes any offence that includes sale or distribution of drugs.
(4) The Maltese system allows the prosecutor to choose the court for the trial, which will affect the range of sanctions available.
Country Penalties for possession Penalties for trafficking (imprisonment) (3)
for personal use (1) (2)
Bulgaria High-risk drugs: 10–15 years High-risk drugs: 10–15 years
Risk drugs: 3–15 years Risk drugs: 3–15 years
Smuggling large quantities: up to 20 years
Involvement in a group: up to 15 years for trafficking, up to life for production
Cyprus Up to life imprisonment, and/or a fine Up to life imprisonment depending on class of drug
Czech Republic Administrative fine 1–5 years
If quantity greater than small: up to 2 years If a larger extent, or involving an organised group: 2–10 years
Involvement in international criminal organisation, or large financial benefit: 10–15 years
Estonia Small quantities: administrative fine or administrative Small quantities: fine or 1 year
detention up to 30 days
Large quantities: as trafficking Large quantities: 1–5 years (if a repeated offence or involved in a group: 2–10 years)
Hungary Small quantity: up to 2 years 2–8 years
If involved in an organised group: 5–10 years
If a large quantity: 5 years to life
Latvia If a small amount (defined): administrative fine or Up to 10 years
administrative detention up to 15 days
Up to 3 years If by group: 5–12 years
If large amounts or especially dangerous substances: 8–15 years
Lithuania Up to 2 years Up to 3 years
If a large amount: 2–8 years
If a very large amount: 5–15 years
Malta (4) Magistrates court: 3–12 months and/or a fine Psychotropic medicines:
Criminal court: 1–10 years Magistrates court: 3–12 months and/or a fine
Criminal court: up to 10 years
All drugs except psychotropic medicines:
Magistrates court: up to 10 years
Criminal court: life, or up to 30 years
Poland If lesser gravity: up to 1 year, limitation of liberty or a fine Up to 8 years
Up to 3 years If considerable quantity: up to 10 years
Romania 2–5 years High risk: 10–20 years
Risk drugs: 3–15 years
Smuggling: up to 25 years
If by an organised group, then up to life
Slovakia Up to 3 years 2–8 years
If of considerable or substantial value: up to 10 years
If in conjunction with an organised group: 12–15 years, or up to life if exceptional
Turkey 1–2 years Sale and related acts: 4–10 years
Sale of cocaine, heroin, morphine: 6–15 years
Import or manufacture: up to 30 years
If by an organised group: increase sentence by half
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Generally, national drug strategies appear to be intended
to last for four to five years. However, in some CEECs it
is felt that longer-term planning is needed if the strategy
is to have an impact on the drug phenomenon. In Hungary,
the 2000 drug strategy set targets up to 2009; and in
Slovakia the national programme against drugs, updated
in 1999, will cover up to the year 2003 with the prospect
of extending it to 2008. Estonia is expected to adopt
a strategy that would remain in place until 2012.
The status of the national drug strategies is another
interesting area. In Romania and Slovakia, the strategy
is reported to be binding on all ministries involved in its
implementation. In particular, the Slovak strategy calls on
each ministry to report annually, in a so-called actualisation
meeting, on its own activities in relation to the national
programme, if necessary revising, goals, tasks, time frames
and financing. In the Czech Republic, activities covered
by the drug strategy are binding to the extent that each
ministry is obliged to adopt its own plan, and to evaluate
the resulting budgetary impact. Similarly, the new Estonian
drug strategy will require administrations to plan their own
activities to meet predefined deadlines. These methods and
instruments ensure greater accountability and execution of
anticipated tasks, even if the national drug strategy in itself
lacks ‘official’ binding powers.
Many of the national drug strategies in the CEECs are
revisions of previous strategies on the drug situation in the
country. In some cases, failure to implement the previous
drug strategy (for political or financial reasons) was the
management criteria, being comprehensive, oriented towards
targets and implementation, and emphasising coordination.
Most national drug strategies in the CEECs have direct links
to the EU drug strategy and the EU action plan on drugs
(2000–04). For example, the six objectives of the EU plan
constitute a core set of aims for the Czech strategy and are
expressly mentioned in the new texts of Estonia and Latvia
as well as in the national drug strategies of Poland and
Romania and in the draft strategies of Lithuania and
Slovenia. This trend also reflects response to the
international demand for a ‘balanced, comprehensive
and multidisciplinary approach’, made to the countries of
the UN system by the United Nations General Assembly
Special Session (Ungass) on drugs in June 1998.
All national drug strategies analysed in this section are
structured to cover actions in the areas of both demand
reduction and supply reduction. In each case, the strategies
outline measures to reinforce or upgrade law enforcement
activities (e.g. police, customs, border patrols), as well as
to establish or strengthen structures and programmes
geared towards improving drug prevention in the
community and treatment and rehabilitation, including, in
many cases, measures to reduce the negative consequences
of drug use. Although this does not automatically ensure
that a ‘balanced approach’ is implemented, the fact that
both sides of the drug problem (demand and supply)
are taken into account in national strategies can be
considered a good starting point.
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Table 5: Current national drug strategies in the candidate countries
Date of adoption Country National strategy
1999 Lithuania National drug control and drug prevention programme, 1999–2003
Slovakia National programme for the fight against drugs (adopted in 1995 and updated in 1999) until 2003 with the prospect of extension
to 2008
2000 Hungary National strategy to combat the drug problem
2001 Czech Republic National drug policy strategy, 2001–04
2002 Bulgaria National anti-drug strategy, 2002–07
Poland National programme for counteracting drug addiction, 2002–05
Romania National strategy on drugs, 2002–04
Slovenia National programme on drugs, 2003–08
2003 (under way; Slovenia National programme on drugs, 2003–08 (not yet adopted at the time of writing)
provisional titles and dates)
Estonia National drug strategy, 2012
Latvia Drug control and drug abuse prevention programme, 2004–08
Lithuania National drug control and drug prevention programme, 2004–07
(24) In the UK, drugs action teams are local permanent structures composed of all actors in the community who are involved with the delivery of the drug
policy.
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motive for conceiving a new document focused more on the
issues of financing, performance and implementation. An
attempt to apply an evidence-based approach lies behind
most of the revision processes. Revision of the current
situation and the involvement of a large number of
professionals are also two key aspects of current national
drug strategies elsewhere in the EU (EMCDDA, 2002d).
In the Czech Republic, for example, the national drug
strategy presents the results of a detailed analysis of the
strengths, weaknesses, opportunities and threats (so-called
SWOT analysis) of current drug policy. This analysis
contributed to the definition of priorities, objectives and tasks
of the new strategy. In Poland, the national programme
against drugs (2002–05) is the result of an extensive
revision of the previous drug strategy (1999–2001), put
together during a three-week seminar. The seminar closed
with a total of nearly 30 experts contributing to the drafting
of the new strategy. Analysis of the current drug situation
and foreseeable trends forms the basis of new strategy
documents in Slovenia and in Estonia. In the latter,
cooperation with Germany in a twinning project was
reported to be a key factor. In Romania, the national
strategy on drugs (2002–04) anticipates broad participation
by governmental and non-governmental institutions working
in the field of drugs, as well as guidance from Spanish
experts as part of a Phare twinning project.
The work undertaken by the Phare assistance programme
and, more recently, under the aegis of Phare twinning
projects (Table 6) seems to have contributed to the
promotion of best practice (at least in the area of
establishing institutions), shaping a culture focused on
delivery and performance. This has had the beneficial effect
of promoting the sharing of competencies and experiences
among old and new members of the EU.
In Latvia, Lithuania and Romania, a twinning project with
Spain played a major role in promoting the adoption of a
new structured policy plan and of a central coordination
agency, along the lines of the Spanish governmental
delegation for the national plan on drugs. In Bulgaria,
the twinning project with the UK has had a clear effect
on the organisation of the delivery of the national drug
strategy at local level by instituting a system of municipal
drug councils, similar in concept to the UK drugs action
teams (24). In addition, French twinning partners have
helped to evaluate the Polish drug strategy.
Goals and themes
In examining national drug strategies three common goals
emerge:
• improve effective implementation and delivery of
coordinated actions in the field;
• establish a realistic approach to illegal drug use and
trafficking;
• reduce problems caused by drugs.
Improving implementation
Improving the effectiveness of implementation appears to
assume particular emphasis in the national strategy of
Bulgaria, where a renewal of national structures and a new
action plan is envisaged, and of Latvia, via better
coordination and guaranteed financing. The new strategy in
Lithuania aims to create a new policy framework for coherent
and widely integrated drug policy, whereas in the Czech
Republic ‘real responsibility’, ‘active participation’ and
cooperation among all governmental and non-governmental
organisations are advocated. Finally, Slovenia’s priorities
generally focus on reinforcing structures and programmes.
Establishing a realistic approach
In Romania and Hungary, more emphasis is placed on
achieving predetermined drugs policy objectives. In
Romania, the overall goal of the strategy is to provide,
through demand and supply reduction, a realistic approach
to illegal drug use and trafficking. The Hungarian strategy
favours a ‘free, confident and productive society’,
‘managing the health, social and criminal hazards and
harms related to drug use and trade’.
Reducing problems
Reducing the problems posed by drugs is emphasised in the
new Estonian strategy and in the national drug strategy of
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Table 6: Phare twinning projects
Country Twinning partner 
Bulgaria United Kingdom
Czech Republic Austria
Estonia Germany
Hungary Spain 
Latvia Spain
Lithuania Spain (leading partner) and Sweden
Poland France
Romania Spain
Slovakia France
Slovenia Spain (leading partner) and Austria
Similar twinning projects are expected to start between Cyprus, Spain and Greece,
and Turkey, Spain and Greece.
Table 7: Main themes in national drug strategies
Bulgaria Balanced policy Strategic coordination Information exchange Local policy delivery
Czech Republic Primary prevention Harm reduction Treatment and rehabilitation Repression
Estonia Prevention Treatment and Harm reduction Supply reduction Drugs in prison Monitoring and 
rehabilitation evaluation
Hungary Community Prevention Social work Therapy and rehabilitation Supply reduction
Latvia Coordination Drug demand Drug supply Monitoring information International 
reduction reduction research evaluation training cooperation
Lithuania Drug demand  Drug supply Monitoring assessment International 
reduction reduction information research evaluation cooperation
Poland Prevention Treatment rehabilitation Health risks reduction Supply reduction Research monitoring 
assessment
Romania Drug demand reduction Drug supply reduction International cooperation
Slovakia Drug demand reduction Drug supply reduction Mass media policy International cooperation
Slovenia Human rights Coordination Support to Global action Decentralisation Public order Special groups in 
programmes populations
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impossible to verify whether the envisaged activities have
(a) been fully implemented, (b) contributed to the
achievement of the fixed objectives or (c) had an impact on
the drug situation. Nevertheless, confining the analysis to
the formal structures of the national strategies, some criteria
that could facilitate the implementation of the stated goals
and objectives can be identified. Most national drug
strategies include performance indicators set against
evaluation tools and detailed objectives for different areas
of intervention. Moreover, the fact that a large number of
professionals have been involved in the conception of most
of the national strategies, and also form part of the
implementation process, is a positive finding.
The national drug strategies of the Czech Republic,
Hungary and Poland, in particular, set down performance
indicators and evaluation tools for short-, medium- and
long-term objectives in the form of a matrix. In addition,
the Estonian strategy includes a biannual implementation
plan (annexed to the new national strategy, 2003), and
the draft of the new Slovenian national programme on
drugs (2003–08) includes a national drug strategy and an
action plan. In Lithuania, the draft drug strategy (2004–07)
comprises an action plan detailing activities, budget and
responsible authorities.
Thus, improving the management and scientific culture
seems to be a key element in the process of implementing
the new national drug strategies. However, as reported
by some countries, this objective-oriented approach might
be cancelled out, in reality, by the lack of appropriate
resources or political will to be allocated to the field of
drugs (Table 8).
Poland. Similarly, the strategy adopted in Slovakia aims to
tackle the health, psychological and social damage caused
by drugs.
The four traditional pillars on which drug policies are based
— prevention, treatment, law enforcement and international
cooperation — are present, to varying degrees, in all of the
national drug strategies that were reviewed. In addition,
cross-analysis reveals three other common principles:
partnership, coordination and scientific monitoring.
Partnership, defined as interaction between ministries and
agencies, is strongly emphasised in many national
documents. Coordination, or the improvement of
coordination and cooperation systems in the field of drugs,
is also the focus of many strategies. Scientific monitoring is
considered important with the aim of basing drugs policy
on scientific evidence rather than assumptions. These three
guiding principles are particularly evident in the national
drug strategies of Bulgaria, the Czech Republic, Estonia,
Hungary, Latvia, Poland and Romania.
In addition, harm reduction is expressly referred to as a
guiding principle of drug strategy in some countries (the
Czech Republic and Estonia); in Poland, the term used is
‘health risks reduction’. Other pillars of drug strategies
include mass media policy in Slovakia, intervention in
prisons in Estonia and implementation at local level in
Bulgaria (Table 7).
Implementation
As far as the implementation of national drug strategies is
concerned, it is clear that without a rigorous evaluation it is
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Evaluation
Despite the proliferation of national strategy documents,
the concept of evaluation is generally considered
infrequently or is less structured than might be expected.
In general, the aim of providing detailed objectives, tasks,
financing, accountability and a timetable is to identify
potential improvements and resolve eventual problems.
While some activities suggestive of an evaluation culture
are emerging in some countries, across the region as
a whole an evaluation culture tends to be lacking. Only a
few examples can be found: in Poland, drug strategy is
evaluated with the support of its twinning programme with
France, and in Bulgaria it appears that the proposed
national anti-drug agency will be in charge of evaluation
of the Bulgarian strategy.
As far as the other countries are concerned, it would be
more accurate to say that a more or less structured ‘process
of monitoring’ is in place. For example, in Hungary, the
Secretariat of the Coordination Committee routinely
conducts interviews and collects data on the implementation
of the national drug strategy. In the Czech Republic, the
various ministerial tasks are annually revised by the
government. This process is coordinated by the Secretariat
of the National Drug Commission. In Slovakia, ‘the
actualisation system’ (see above) allows for annual review
and redirection of national drug strategy activities, and in
Slovenia the new national action plan (envisaged in the
2004–04 drug strategy) is to be audited biannually, in
association with preparation of the national budget, which
takes place every two years. In addition, the new Lithuanian
strategy foresees the establishment of a drug control
department, which will report to the government and will be
responsible for management, control, evaluation and
implementation of the strategy.
Some countries are in the process of implementing, or are
about to adopt, their second or third national strategic
plan, and yet still make no clear reference to scientific
evaluation. Further work could be carried out in this area.
Financing
Out of 10 national drug strategies analysed, only that of
Lithuania provides an indication, ‘on paper’, of the costs of
planned activities. In the other countries, the national drug
strategy does not have a specific budget, and the ministries
or institutions involved are more or less expected to finance
their tasks out of their own budget allocation.
The issue of financing in general is considered in the
national strategies of Poland and Romania, each of which
dedicates a specific chapter of the document to this subject.
In the Czech Republic, where the issue of financing is
regarded as an objective with long, medium and short-term
goals, each ministry is called on to evaluate the budgetary
impact of the activities identified in the strategy. In Estonia,
too, the new strategy envisages that each ministry will
earmark funds to be used in the implementation of its own
activities.
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Bulgaria The national drug strategy sets out 22 tasks divided between demand reduction (12) and drug supply reduction (10).
Czech Republic The strategy, which is to be implemented by both public and private authorities, identifies over 80 tasks, presented in an annex to the strategy document.
Estonia Each chapter of the strategy includes one long-term objective for the year 2012 and mid-term objectives for the year 2007.
Hungary Each of the four main objectives is subdivided into short-, medium- and long-term objectives. Dates for achievement are, respectively, 2000, 2002 and 2009.
Latvia The new drug programme to be adopted in 2003 puts the accent on delivery and measurable performance, being structured by goals, objectives and targets.
Lithuania The draft of the national drug strategy contains a detailed list of measures to be carried out, identifying who is responsible for execution, the date for achievement and
anticipated expenditure for the year of reference, together with the required funds and the financing source.
Poland Objectives and tasks are identified and developed, looking at their measurability. The strategy focuses particularly on clear identification of accountability, responsibility
and financial allocation. Time scales and estimated costs for each institution are also included.
Romania General and specific objectives and action plans are identified, and each ministry has its own plan of action in line with the aims of the national drug strategy.
Deadlines for evaluation are set for 2003 and 2004.
Slovakia Each general objective has a set of sub-objectives to be achieved: nine in the area of demand reduction, eight in the area of drug supply reduction and law
enforcement, three in the mass media policy area, and six in the international cooperation area.
Slovenia In the future strategy, objectives are divided into general objectives (to 2002–08), mid-term objectives (from 2004 to 2006) and priorities (until the year 2004).
Concrete actions with clear definitions will be listed in the action plan.
Table 8: Examples of the objective-oriented approach in the CEECs’ national drug strategies
(25) The 15 EU Member States plus Norway.
(26) This is the expression used in current terminology (especially in the international arena) to label those responsible for drug coordination at national level.
The expression ‘national drug coordinator’ is not consolidated at European level.
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Permanent coordination units
The second level is represented by a more technical unit
composed of technicians and professionals. Its role usually
includes coordinating and planning national drug strategy
on a permanent basis and, depending on the country,
perhaps also monitoring and exchange of information.
In four countries (Bulgaria, the Czech Republic, Hungary
and Slovakia), these functions are performed by the
secretariats of the interministerial committees. In the
remaining countries the task of permanent coordination
is performed by other governmental drug coordination units
(Table 10). In the Czech Republic, Poland, Slovakia,
and in the future in Romania, the national focal points
of the Reitox network come under the auspices of these
coordination units.
The two-level structure is similar to the model of
coordination adopted in many EU countries. However,
in the current Member States, the technical coordination
units tend to have a more important role, being
increasingly responsible for coordinating the day-to-day
implementation of drug strategy, leaving interministerial
committees to make the strategic and political decisions.
Responsibility for drug coordination appears to lie with
one of the government departments traditionally involved in
drug policy, but which one varies from country to country.
As shown in Figure 17, responsibility for drug coordination
lies in five cases within the Ministry of Health or Social
Affairs, in two cases with the Ministry of the Interior and
in three countries with the Council of Ministers. In Slovenia,
it is intended that responsibility for drug coordination will
in the near future be transferred from the Prime Minister’s
office to the Ministry of Health. These findings reflect
the situation in the EU at present, with 12 out of 16
Member States (25) having allocated the responsibility of
drug coordination to ministries dealing with social matters.
Although responsibility for drug coordination is relatively
clear-cut in the 10 CEECs, the role of national coordinator
(as found in the EU countries) is less well developed. In the
CEECs, the head of either the interministerial committee or
the permanent coordination unit (Tables 9 and 10) usually
assumes the typical role of national drug coordinator (26),
which mainly involves control and reporting at a political
level, acting as a link between workers in the field and
decision-makers, and coordinating, managing and
assuming public accountability. However, comparison
between countries is not possible as the term ‘national
drug coordinator’ is not defined in the national drug
strategies of the CEECs.
Lack of financing was frequently cited as the reason for
non-implementation of previous policy plans and/or
coordination structures, especially in Latvia and Lithuania.
In some countries, although the issue of financing the
national drug strategy is important, more serious problems
than drug abuse (e.g. poverty and alcoholism) are higher in
the list of national priorities.
Coordination
There is widespread consensus in the CEECs about the need
to enhance cooperation and coordination among all actors
involved at governmental and non-governmental level in
order to implement drug policy effectively. Indeed, national
drug strategies often cite improved coordination as a main
objective, a prerequisite for the achievement of which is a
stronger political will and greater resources. The lack of
uniform data and information from all countries makes it
difficult to present comprehensive and in-depth
comparisons. However, one observation that can be made
is that, throughout the region, coordination seems to rely on
a uniform, two-level model composed of an interministerial
committee and a technical body (Figure 16).
Interministerial committee
In all the CEECs, an interministerial committee, whether
designated National Drugs Commission, Board of Ministers
or National Drugs Council, ensures drug coordination at a
political level. The interministerial committee is the main
coordination authority and is made up of representatives of
all ministries and public agencies involved in the delivery of
drug policy. In most cases, it acts as the government’s
advisory, coordination and initiation body in the field of
drugs. In some cases, it is also responsible for control
activities. The committees normally meet two to four times a
year, with meetings often timed to coincide with important
events, such as revision of laws, drawing up of drug plans
or preparation of strategic documents. Ministers and
Secretaries of State are required to participate, in person,
in those meetings (Table 9).
66
Figure 16: Model of coordination of national drug policy
Interministerial committee 
Interministerial coordination 
(regular meetings among 
main ministries involved)
Coordination unit/secretariat 
of the interministerial committee 
Day-to-day coordination activity 
(technicians and professionals)
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The implementation of drug coordination, despite
appearing well structured ‘on paper’, has run into some
obstacles in some countries. For example, in Estonia, the
interministerial committee established in 1996 to ensure
coordination of national drug policy held no meetings
between 2000 and 2002. And in Latvia, the National Drug
Control and Drug Abuse Prevention Coordination
Commission, created in 1993, has hardly been operational
since 1996 and was not operational at all in 2002 because
it lacked an executive secretary, staff members and a
specific budget. Finally, in Romania, the interministerial
committee met only on rare occasions, and in December
2002 it was replaced by the National Anti-Drugs Agency.
Modification of institutional frameworks and the creation of
new central permanent coordination bodies, especially with
the assistance of twinning partners, is often seen by the
CEECs as a chance to introduce more effective concepts
Table 9: Interministerial committees in charge of coordination in the field of drugs
(1) In Latvia, the new strategy envisages the establishment of a new central coordination body.
(2) In Lithuania, the draft strategy envisages the establishment of a new central coordination body, the drug control department, reporting to the government.
(3) In Romania, the Interministerial Committee for the Fight against Drugs was wound up in December 2002 when the new Anti-Drugs National Agency was created.
(1) In Bulgaria, the new strategy proposes the establishment of a drugs policy coordination and analysis unit.
Country Permanent coordination offices Location
Bulgaria Secretariat of the National Drug Council (1) Ministry of Health 
Czech Republic Secretariat of the National Drugs Commission Council of Ministers 
Estonia Department of Public Health Ministry of Social Affairs
Hungary Secretariat of the Coordination Committee on Drug Affairs Ministry of Children, Youth and Sport
Latvia n.a.
Lithuania Secretariat of the Governmental Drug Control Commission State Public Health Service
Poland National Bureau for Drug Prevention (including the Secretariat of the Interministerial Council) Ministry of Health
Romania Anti-Drugs National Agency Ministry of the Interior
Slovakia Secretariat of the Board of Ministers for Drug Dependencies and Drug Control Council of Ministers 
Slovenia Government Office for Drugs Council of Ministers 
Country Interministerial committee Chair
Bulgaria National Drugs Council Minister for Health
Czech Republic National Drugs Commission Prime Minister; Executive Vice-Chairman: Deputy Prime Minister
Estonia Ministers’ Committee on Drug Policy Minister for Social Affairs
Hungary Coordination Committee on Drug Affairs Co-Chairs: Ministers for Children, Youth and Sport and Health, Social and Family Affairs
Latvia National Drug Control and Drug Abuse Prevention Minister for the Interior
Coordination Commission (1)
Lithuania Governmental Drug Control Commission (2) Minister for Health
Poland Council for Counteracting Drug Addiction Deputy Minister for Health
Romania n.a. (3)
Slovakia Board of Ministers for Drug Dependencies and Drug Control Deputy Prime Minister for EU Integration, Human Rights and Minorities
Slovenia Interministerial Drug Commission Minister for Health
Table 10: Permanent coordination units and their location within governmental administrations
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Bulgaria, following the twinning project with the UK,
Municipal Drugs Councils (MDCs) have been established at
local level. Made up of senior representatives of all
agencies, institutions and organisations dealing with drug
issues in the municipality, their main objective is the
delivery of the national strategy and the action plan at
local/municipal level. To this end, MDCs are asked to adopt
municipal and regional action plans for the prevention of
drug use and treatment of drug users. Once again, only
further investigation can reveal the true extent of drug
coordination at the local level.
Conclusions
All acceding and candidate countries have been active in
the legislative field since 1990. Although, initially, for
historical reasons, legislation shared similarities in many of
the countries, it is clear that subsequent movements have
taken very different directions. As amendments to the penal
code have been enacted in a number of countries even in
the last three years, the dust has not yet settled. The
majority of countries treat possession of a small amount of
drugs for personal use as a criminal offence, but three
countries consider this to be an administrative violation.
Bulgaria and Hungary do not address the intent of any
possession in their legal provisions but take into account
the degree of addiction of the offender as a reason for
leniency. Sentences for trafficking are similar to those
in the current EU Member States.
and instruments of coordination. In this regard, a drugs
policy coordination and analysis unit is to be established in
Bulgaria to support the National Drug Council and to
coordinate the delivery of the strategy across ministries.
In Latvia, a new, central coordination body is envisaged
(the national drug agency).
As far as the scope of coordination is concerned,
insufficient information is available to analyse the remit of
coordination bodies, either interministerial committees or
permanent coordination units, and to analyse whether their
powers extend to global coordination, involving all aspects
of drugs policy, or only to specific areas, e.g. demand or
supply reduction. Further research is needed to assess the
true extent of global coordination.
Coordination in the field of drugs is, of course, very
important, particularly at regional and local level, where
the political objectives of national drug strategies have to
be translated into actions on the ground. Local drug
coordination initiatives are reported from several CEECs. In
the Czech Republic, drugs commissions are responsible for
overseeing the implementation of regional drug policy
strategies and are headed by a regional coordinator. In
Hungary, the Coordination Fora on Drug Affairs have
started to operate at local level to coordinate local drug
demand reduction activities. In Estonia, Councils of Drug
Prevention have been established in all counties since
2002, and in Romania a network of 47 centres for
counselling and anti-drugs activities is in place. Finally, in
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Health/Social Affairs Interior Council of Ministers
Bulgaria 
Ministry of Health
Estonia 
Ministry of Social Affairs
Hungary 
Ministry of Children, Youth and Sport; 
Ministry of Health,  
Social and Family Affairs
Lithuania 
Ministry of Health
Poland 
Ministry of Health
Latvia 
Ministry of the Interior
Romania 
Ministry of the Interior
Czech Republic 
Office of the Government
Slovakia 
Deputy Prime Minister responsible 
for EU Integration, Human Rights 
and Minorities
Slovenia 
Government office for drugs 
(temporary situation)
Figure 17: Main responsibility for coordination in the field of drugs in the national administrations
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It is commendable that, even within this relatively short time
scale, the Czech Republic and Hungary have planned and
carried out some form of scientific evaluation or impact
analysis of their legal changes, and then have had the
confidence to take action on the results of that evaluation.
Policy plans in the form of national drug strategies are in
place, or are about to be adopted, in all CEECs. These
documents are based on a global approach, set objectives
and deadlines, refer to the EU drug strategy’s objectives
and identify responsibility for implementation. Therefore
‘formally’ and in general terms, the CEECs seem to be
moving in the direction of a ‘balanced, comprehensive
and multidisciplinary approach’ (Ungass, 1998).
However, this official picture should be compared with the
implementation of these national strategies in the field at
regional and local level.
As far as coordination is concerned, joining together the few
elements collected it is apparent that coordination of drug
policy in the CEECs appears to be quite a new concept. In
some countries, the national coordination systems are very
new and are therefore not yet fully operational, while in
others coordination structures, although they have been in
place for some time, have not been implemented owing to
lack of resources. In a few countries, the coordination bodies
seem to focus specifically on drug demand reduction rather
than on all aspects of drug policy. In some, the systems of
regular ministerial reporting and auditing are reported to be
efficient. This picture should be revisited when more detailed
and accurate data become available.
In the course of drafting this chapter professionals
working in the national focal points as well as
government officials were asked for their opinion on
what, if necessary, could be done to improve the
national strategy and drug coordination system. The
answers, which took into account local characteristics
and needs, revealed some common views.
In general, it is recognised that the new national drug
strategies, compared with the previous ones, more
closely meet the requirements of a ‘balanced,
multidisciplinary and comprehensive approach’ to drug
policy. It is also acknowledged that more effort should
be put into ensuring the effectiveness of programmes
and projects and in the overall management of the
strategy. This could perhaps be achieved by improving
collaboration among institutions involved in the
implementation and upgrading the skills of the staff
and actors involved. A second aspect on which there is
broad agreement is that coordination units should have
some executive power in terms of management and
coordination of the national drug strategy. The lack
of executive power is sometimes seen as the weak point
of coordination bodies. A management culture should
also be encouraged and implemented, with the focus
on intensive communication and clarification of
competencies and roles. Finally, it was emphasised
that at EU level it would be extremely helpful to
organise regular annual meetings of those responsible
for coordination, implementation and evaluation
of national strategies.
The research conducted during the preparation of this
chapter suggests that the drug strategies of the CEECs
broadly satisfy the vision outlined by professionals and
officials interviewed. They tend to be comprehensive,
centrally coordinated and orientated towards a global
long-term approach, and some are also structured to
monitor performance. This might be the result of the
involvement of experts and professionals in the field (from
EU countries too), in the drafting and sometimes also in
the conception phase. 
However, it is clear that the desire to work towards a
‘modern drug policy’, centrally coordinated and structured
in objectives, targets and performance indicators, if it is to
be fulfilled, needs a strong political and financial will and
greater attention to effectiveness.
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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
is one of the European Union’s decentralised agencies. Established in 1993
and based in Lisbon, it is the central source of comprehensive information
on drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates objective, reliable and
comparable information on drugs and drug addiction. In doing so, it
provides its audiences with an evidence-based picture of the drug
phenomenon at European level. 
The Centre’s publications are a prime source of information for a wide
range of audiences including policy-makers and their advisors;
professionals and researchers working in the drugs field; and, more
broadly, the media and general public.
This annual report presents the EMCDDA’s yearly overview of the drug
phenomenon in the acceding and candidate countries to the European
Union. The printed publication is complemented by an online version
available at: http://candidates.emcdda.eu.int.
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